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ABSTRACT 
EXPRESSION OF CBMP4 PROTEIN 
AND ANTI-CBMP4 MONOCLONAL ANTIBODY PRODUCTION 
by Xuezhi Li 
Malformations during cardiac valve development are some of the most common 
congenital heart defects. Recent studies on BMP4 in heart development reveal that this 
secreted protein plays key roles in cardiac cushion formation, differentiation and cushion 
cells apoptosis. While a few papers have investigated BMP4 transcription patterns at 
various times during heart development, a clear mapping of cardiac BMP4 expression 
domains has yet to be accomplished. Studies at the protein levels are particularly 
hampered in the chick by the lack of suitable specific anti-cBMP4 antibodies. To address 
this need, chick recombinant BMP4 was cloned, expressed and purified in both COS-7 
cells and in E. coli for anti-cBMP4 monoclonal antibody (mAb) production. In addition, 
a BMP4 synthetic peptide was used to produce anti-cBMP4 mAb that could be used for 
future immunohistochemistry studies to map the spatio-temporal pattern of BMP4 protein 
expression during heart development. 
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Introduction 
Congenital Heart Disease 
Congenital heart malformation is the most common human birth defect and the 
leading cause of death in the first year of life (Hoffman, 1995). It is estimated that the 
US population of adults with congenital heart disease was about 8,000,000 in 2000 
(Warnes, Liberthson, & Danielson, 2001). Most congenital heart malformation is due to 
the defects of septation or valvegenesis events during embryonic heart development. For 
example, one of the most frequently diagnosed disorders is atrioventricular canal defect 
(AVCD), which accounts for 7.3% of all congenital heart abnormalities (Pierpont, 
Markwald, & Lin, 2000). AVCD covers a spectrum of abnormalities. The partial form 
of AVCD is caused by a deficiency in atrial septum primum (ASP) formation, whereas 
the complete form is due to the absence of AV septum, resulting in the formation of a 
single common atrioventricular canal (Digilio, Marino, Giannotti, Di Donato, & 
Dallapiccola, 2000). The process of embryonic cardiogenesis has been extensively 
studied at both the anatomical and molecular levels using animal models, enhancing our 
understanding of the mechanisms underlying cardiac morphogenesis and the 
pathogenesis of congenital heart defects. 
Embryonic Heart Development 
The heart is the first organ to form and function during vertebrate embryogenesis. 
Heart development is a complex process that involves a series of cellular migrations, 
fusions, and specific differentiations. Due to the evolutionary conservation of many of 
these processes, major insights of embryonic cardiogenesis have been gained from the 
1 
studies of chick embryos. In the pregastrula chick embryo, cells that contribute to the 
heart are found within the posterior half of the epiblast (Hatada & Stern, 1994; Rawles, 
1943). During early gastrulation stage, cardiac precursor cells migrate to a region of the 
primitive streak caudal to Hensen's node. Thereafter, they migrate into the mesoderm 
and spread anterolaterally, resulting in the formation of right and left precardiac 
mesoderms (Garcia-Martinez & Schoenwolf, 1993; Rosenquist & DeHaan, 1966). At 
Hamburger and Hamilton (HH) 6, the bilateral regions then condense, which later forms 
a cardiac crescent that subsequently coalesces at the ventral midline to form a linear heart 
tube. The heart tube is composed of a thin outer myocardium and an inner endocardium. 
The myocardium secretes a thick extracellular matrix called the cardiac jelly that 
separates the myocardium and endocardium (Kirby, 2002). The heart tube expands and 
bends to the right side of the embryo and later the heart tube twists dramatically and 
forms a d-loop. As the development proceeds, the heart tube dilates, elongates and twists 
in a right-handed manner, realigning the prospective chambers so that the forming atrium 
is to the left and cephalic to the ventricle. At the same time, presumptive cardiac 
segments begin to appear, which make up the conus cordis or outflow tract (OT), 
primitive right and left ventricles, atrioventricular canal (AVC), atrium, and the sinus 
venous. After the completion of the d-loop, some of the endocardial cells of the OT and 
AV segments of the single heart tube change their phenotype to that of mesenchymal 
cells. These then migrate into the adjacent cardiac jelly to form endocardial cushion 
tissue, the primordial of the valves and cardiac septa of the adult heart. This embryonic 
phenomenon involves what is called epithelial-mesenchymal transformation (EMT). At 
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this time, ectomesenchyme originating from the cardiac neural crest migrates into the 
cardiac OT via the arterial pole. Thereafter, the endothelially derived mesenchyme and 
the neural crest-derived mesenchyme develop the outflow septum, semilunar valves and 
the aorticopulmonary septum, respectively. The AV endocardial cushion tissue develops 
to form the leaflets of the AV valves and the AV septum. As development proceeds, the 
aorticopulmonary septum, outflow septum, interventricular septum (muscular ridge of the 
interventricular foramen), AV septum, and primary atrial septum come into alignment 
and fuse with each other, resulting in the completion of the four-chambered heart. At this 
point the heart resembles its mature form (Larsen, 2001; Nakajima, Yamagishi, Hokari, 
& Nakamura, 2000). 
TGF-0 Superfamily and Bone Morphogenetic Proteins 
The regulatory factors involved in the process of septation and valvegenesis are 
heavily investigated, with numerous studies indicating that members of the transforming 
growth factor- /3 (TGF-/3) of signaling molecules are involved. The TGF-/3 superfamily is 
composed of over 30 structurally related members with diverse functions in development. 
Based on sequence homology and signaling mechanisms, the TGF- /3 superfamily 
includes i) the TGF- /5 family, ii) the activin family, iii) the bone morphogenetic proteins 
(BMPs), iv) the Vgl family, and v) other proteins, including glial-derived neurotrophic 
factor and Mtillerian inhibitory factor (Hogan, 1996; Gilbert, 2003). The protein encoded 
by TGF- (3 superfamily gene is synthesized as a large pre-protein, consisting of a 
hydrophobic signal peptide, an N- terminal pre-domain and a C-terminal biologically 
active peptide (Herpin, Lelong, & Favrel, 2004). After protein processing, only the 
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carboxy-terminal region contains the active mature peptide with the TGF-/3 domain. 
Then the mature peptides are dimerized into homodimers (with themselves) or 
heterodimers (with other TGF- jS peptides) and are secreted from the cell for various 
functions (Gilbert, 2003). 
The BMPs constitute the largest family. They were originally identified from 
bone matrix using an ectopic bone formation assay (Wozney, 1992). To date, around 20 
BMP family members have been identified and characterized. Based on sequence 
homology, there are six main groups: i) the Dpp subgroup, related to Drosophila 
decapentaplegic (dpp), consists of BMP2 and BMP4; ii) the 60 A subgroup, related to 
Drosophia 60 A protein, consists of BMP5, BMP6, BMP7, BMP8 (Zhao, 2003); iii) 
BMP3A and BMP3B; iv) BMP9 and BMP10; v) BMP 12, BMP 13 and BMP 14, and vi) 
BMP11 and growth/ differentiation factor 8 (Chen, 2004). 
BMPs are 30-38 kD homodimers that are synthesized as prepeptides of 
approximately 400-525 amino acids. The mature C terminal domain of BMPs usually 
contains 100-140 amino acid residues after protein processing and dimerizes for 
bioactivity. BMP proteins act through type I and type II receptors that are single-pass 
transmembrane proteins with serine/threonine kinase domains on the cytosolic side of the 
plasma membrane. Both type I and type II receptor are required for signaling. Three 
types of type I receptors have been shown to bind BMP ligands, and they are type IA 
receptor (BMPR1A or ALK3), IB receptor ( BMPR1B or ALK6) and type IA activin 
receptor (ActRl A or ALK2)(Koening et al., 1994, Macias-Silva, Hoodless, Tang, 
Buchwald, & Wrana, 1998; Ten Dijke et al, 1994). Three type II receptors for BMPs 
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have also been identified and they are type II receptor (BMPR II), type II and IIB activin 
receptors (ActR II and Act R IIB). Whereas BMPR1 A, BMPR IB and BMPR II are 
specific to BMPs, ActRl A, ActR II and ActR IIB are also signal receptors for activins 
(Kawabata, Chytil, & Moses, 1995; Yamashita et al., 1995). Signal transduction through 
serine/threonine kinase receptors has been best characterized in the TGF-/3 receptor 
system. It is likely that BMP receptors transduce signals in a similar fashion. Typically, 
the ligand first binds to and activates a type II receptor homodimer which recruits, 
phosphorylates, and activates a type I receptor homodimer, forming an active tetrameric 
receptor complex. The type I receptor directly binds and phosphorylates a group of 
regulatory proteins belonging to Smad family. In mammals, eight members of the Smad 
protein family have been identified, and these have been grouped into three different 
classes based on structures and functions (Balemans & Van Hul, 2002). One class of 
Smads consists of the receptor-regulated Smads (R-Smads) that act as latent transcription 
factors. R-Smads transiently associate with the type I receptor and are phosphorylated on 
their C-terminus by the type I receptor kinase domain. Phosphorylated R-Smads then 
interact with the co-Smad, Smad4, resulting in translocation of the heteromeric complex 
to the nucleus where it interacts with cell-specific transcription factors to induce target 
gene expression (Piek, Moustakas, Kurisaki, Heldin, & Ten Dijke, 1999). Binding of 
different TGF-/3 family members to their respective receptors results in the activation of 
different R-Smads. Smads2 and 3 are specifically activated by activin/ TGF-/3 signaling, 
whereas Smads 1, 5 and 8 are activated upon BMP stimulation. The last class of Smads 
consists of the inhibitory Smads, Smads6 and Smads7, which function as negative 
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regulators of signaling. Smad6 primarily regulates BMP signaling by competing with 
Smad4 for binding to activated Smadl, resulting in the formation of an inactive 
Smad6/Smadl complex (Hata, Lagna, Massague, & Hemmati-Brivanlou, 1998). Smad7, 
which lacks the conserved C-terminal phosphorylation site of R-Smads, is unable to 
translocate to the nucleus and downregulates BMP, activin, and TGF-/3 signaling by 
inhibiting the phosphorylation of R-Smads through competition with R-Smads for type I 
receptor binding (Hayashi et al., 1997). 
Bone Morphogenetic Protein 4 and Functions 
One member of BMP family is bone morphogenetic protein 4 (BMP4). It is a 405 
residue pre-protein in the chick. It contains a signal peptide region from residue 1 to 19, 
a pre-peptide region from residue 20 to 291 and a mature chain (cleaved post-
translationally) from residue 292 to 405, comprising an active carboxyl- terminal peptide 
of 114 residues. There are four N-linked glycosylation sites at residue 114, 208, 343 and 
362 respectively. Each BMP4 monomer is held together by disulphide bridges between 
three pairs of cysteines in a conformation called the cysteine knot. BMP4 is a secreted 
protein and its structure is closely related to BMP2. Thus, BMP4 is also named BMP2B. 
BMP4 plays an important role in embryogenesis. Early studies using Xenopus 
embryos indicate that BMP4 is a powerful ventralizing molecule. If the mRNA for 
BMP4 is injected into Xenopus eggs, all the mesoderm in the embryo becomes 
ventrolateral mesoderm, and no involution occurs at the blastopore lip (Dale, Howes, 
Price, & Smith, 1992; Jones, Lyons, Lapan, Wright, & Hogan, 1992). Conversely, 
overexpression of a dominant negative BMP4 receptor results in the formation of two 
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dorsal axes (Graff Thies, Song, Celeste, & Melton, 1994; Suzuki et al., 1994). When 
BMP binds to ectodermal cells, it activates the expression of genes such as msxl, which 
induce the expression of epidermal-specific genes, while inhibiting those genes that 
would produce a neural phenotype (Suzuki, Ueno, & Hemmati-Brivanlou, 1997). The 
mechanism of ventral ectoderm (epidermis) induction is depended on the formation of a 
BMP4 gradient. The gradient of BMP4 activity, largely established by organizer-
secreted BMP4 antagonists such as chordin, noggin, and follistatin through binding and 
thus inhibition of BMP4 activity (Dale & Wardle, 1999; Harland & Gerhart, 1997) 
specifies the different mesodermal territories along the marginal zone of the Xenopus 
gastrula. In particular, high levels of BMP4 activity specify ventral mesoderm fates such 
as blood, intermediate BMP levels specify more lateral mesoderm derivatives such as 
kidney, and low levels of BMP activity (in the region closest to the organizer) specify 
dorsal fates such as muscle (Winnier, Blessing, Labosky, & Hogan, 1995). 
A large number of studies in several different species have implicated a key role 
of BMP4 hematopoietic commitment. Huber et al. (1998) has demonstrated that BMP4 
together with either basic fibroblast growth factor or activin A can induce the formation 
of red blood cells from non-mesodermal structures using Xenopus embryos and explant 
assays. Furthermore, hematopoietic commitment induced by the GATA binding 
transcription factors GATA1 and GATA2 requires intact BMP signaling (Huber, Zhou, 
Mead, & Zon, 1998; Maeno et al., 1996). Mice lacking BMP4 died between embryonic 
day 7.5 to 7.9 (E7.5 to E9.5) exhibiting severe defects in mesoderm formation and the 
embryos that survive up to E9.5 show defective blood islands (Winnier et al., 1995). In 
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addition, it is recently demonstrated that BMP4, in combination with cytokines, promotes 
hematopoietic differentiation of human embryonic stem cells (Chadwick et al., 2003). 
BMP4 may act as an important positive regulator of both proliferation and survival of 
human stem cells (HSCs). Bhatia et al. (1999) found that low concentration of BMP4 
promoted proliferation and differentiation of CD34+CD38"Lin" cells while high 
concentration of BMP4 extended the duration of stem cell activity in Nonobese 
Diabetic/Severe Combined Immunodeficiency (NOD/SCED) mice transplanted with 
purified HSC (CD34+CD38"Lin") from human hematopoietic tissue following ex vivo 
culture in serum free medium. Thus BMP4 is acting as a survival factor, preserving the 
sternness of the hematopoietic cells. 
BMP4 is also involved in organ development. The lung appears from the ventral 
foregut as two primary buds, each consisting three layers: the inner epithelium (of 
endodermal origin), the surrounding mesenchymal stroma, and a thin outer mesothelium. 
Early in development, the epithelium undergoes a stereotypic pattern of branching 
morphogenesis to form the conducting airways, a process regulated by epithelial-
mesenchymal interactions (Cardoso, 2001). In vitro studies indicate that exposure of 
lung explants and their associated mesenchyme to BMP4 results in stimulation of 
branching and epithelia cell proliferation (Bragg, Moses, & Serra, 2001). BMP4 is 
expressed in lung mesenchyme with the highest expression adjacent to the proximal 
epithelium, including expression in parabronchial smooth muscle (PBSM) cells (Weaver, 
Batts, & Hogan, 2003). Possibly, the mechanism of BMP4 regulating lung branching is 
through inducing PBSM precursor cells differentiation into PBSM cell lineage (Mailleux, 
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Kelly, & Veltmaat, 2005). PBSM cells are found surrounding the proximal air ways 
(Yamada, Suzuki, Gejyo, & Ushik., 2002), and may participate in embryonic lung growth 
by a stretch-induced signaling mechanism (Sparrow & Lamb, 2003). Fetal PBSM is 
spontaneously contractile throughout gestation, resulting in the stretching of the fetal 
pulmonary epithelium and mesenchyme (Schittny, Miserocchi & Sparrow, 2000). It is 
possible that the contractility of PBSM may result in the release of growth factors, 
signaling molecules, or the regulation of gene expression with consequent effects on lung 
cell growth and differentiation (Nakamura & McCray, 2000). 
Bone Morphogenetic Protein 4 and Heart 
Gene expression and in vitro explant assays suggests that BMP4 is a key 
myocardial signal in initiating epithelial-mesenchymal transformation (EMT) and driving 
the formation and/or differentiation of the cardiac cushions (the precursor to the heart 
valves and immediately adjacent areas). Because of its spatio-temporal patterns of 
expression, BMP4 is, in fact, thought to play a role in induction and maturation of the 
cushions in both the OFT and the AVC. Time course study of BMP4 mRNA expression 
domain within the mouse developing heart tube by in situ hybridization found its 
expression is restricted to the myocardium in cushion-forming segments of the AVC at 
E9.5. At E10.5, however, BMP4 expression switched to the myocardium of the OFT, 
becoming absent from the AVC (Jones, Lyons & Hogan, 1991). More recently, the 
expression domain of BMP4 mRNA has been further investigated and its role in cushion 
formation confirmed by another study using chick embryos to map the expression pattern 
of BMP isoforms using in situ hybridization (Somi, Buffing, Moorman, & Van Den Hoff, 
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2004). Somi et al. (2004) found that BMP4 was expressed in the distal myocardial 
border of the OFT during recruitment of mesodermal cells to the OFT myocardium at 
HH10-11. As heart development proceeded, BMP4 was expressed in the cardiomyocytes 
that protruded into the mesenchyme during muscularization of the atrioventricular 
cushions and the tricuspid valve at HH 33. In addition to studies focused on BMP4 
transcripts expression patterns using in situ hybridization, the immunolocalization of 
BMP4 protein expression was also investigated recently. Using polyclonal antibody to 
immunolocalize the expression domain of BMP4, Keyes et al. (2003) demonstrated that 
BMP4 was only expressed in myocardia, not in the cushions in both chick and mouse. At 
chick E5 to E6, for example, BMP4 was expressed restrictly to the myocardium of the 
OFT. BMP4, however, may not be acting alone. In vitro explant assay involving the 
explanation of heart tube in three dimensional collagen gels indicates that BMP4 by 
itself is unable to induce cushion formation, suggesting the involvement of additional 
factors (Mjaatvedt, Lepera, & Markwald, 1987). 
Investigation of BMP4 function in cardiac development has been hampered by the 
early embryonic lethality of BMP4 null mutant embryos (Lawson et al., 1999). Jiao et al. 
(2003) overcame this difficulty by combining use of a hypomorphic BMP4 allele with a 
Cre/Loxp approach to manipulate levels of BMP4 expression specifically in 
cardiomyocytes. Their findings, however, were contrary to previous hypotheses. They 
showed that BMP4 was dispensable for the initiation of cushion formation but was 
uniquely required for proper AV septation after cushions have formed. In the developing 
mouse hearts, even BMP4 was completely deleted, the EMT was normally initiated. In 
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contrast, after cushions have formed, a modest reduction and a more severe reduction in 
BMP4 gene expression in mutant mice caused the partial and complete form of AVCD. 
Nevertheless, the idea that many other BMPs (BMP2, BMP5, BMP6, BMP7, BMP10) 
are coexpressed in the embryonic heart and may compensate for the loss of BMP4 
(Dudley & Robertson, 1997; Lyons, Pelton, & Hogan, 1990; Lyons, Hogan, & Robertson, 
1995; Neuhaus, Rosen, & Thies 1999; Somi et al., 2004) compromises their conclusion 
that BMP4 was dispensable for initiation of cushion formation. Thus gene targeting 
approaches require double or even triple knockouts to uncover the role of BMP4 during 
heart development due to the overlapping expression pattern of BMP family. 
Another theory as to the possible functions of the BMP4 in the early stage of heart 
development is that BMP4 is involved in the initiation of an apoptotic molecular cascade 
in a sub-population of cushion cells (Zhao & Rivkees, 2000; Abdelwahid, Rice, 
Pelliniemi, & Jokinen, 2001). Existing evidence for an in vivo role for BMPs in the 
induction of apoptosis is inconsistent. BMP4 has previously been shown to induce cell 
death in tissue culture explants of the endocardial cushions of the OT and AV regions 
(Zhao et al., 2000). Somi et al. (2004) made this theory more attractive. They found that 
at the site of delamination, BMP4 mRNA was expressed at interface of myocardium and 
cushion tissue. During digit formation, BMP4 was found to be essential in the regulation 
of interdigital cell death (Merino, Ganan, Macias, Rodriguez-Leon, & Hurle 1999; Tang 
et al., 2000). These observations suggested a role for BMP4 in mediating cell death in 
delamination of the valve in order to make the valve move freely. However, Allen et al. 
(2001) failed to find an increase in the levels of apoptosis in the cushions by 
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overexpressing retroviral noggin (antagonist of BMP4) to inhibit BMP4 signaling. 
Interestingly, mice deficient for intracellular BMP-signaling molecule, Smad 6 
(inhibiting BMP4 signal transduction pathway), developed severe cardiac defects, with 
hyperplasia of the cardiac valves and defects of septation in the OT (Galvin et al., 2000). 
Taken together, no unequivocal evidence supports a role for BMP4 in the induction of 
apoptosis in the developing heart. 
Specific Aim 
The objective of this research project was to produce anti-chick BMP4 
monoclonal antibodies (mAbs) for use in a time-course study of BMP4 expression 
domains during chick cardiogenesis. 
Experimental Design 
In order to produce anti-chick BMP4 monoclonal antibodies, two approaches 
were carried on in parallel: i) Express recombinant chick BMP4 protein (cBMP4) in both 
prokaryotes and eukaryotes and ii) direct produce monoclonal antibodies using cBMP4 
peptides. Primer sets were first designed and tested to allow capture of i) the entire open 
reading frame of cBMP4 and ii) that portion of the cBMP4 coding region giving rise to 
the mature (normally proteolytically derived) fragment of cBMP4 (mcBMP4). Second, 
the successfully amplified PCR products encoding the mature region were purified, 
linearized and cloned into pcDNA4/HisMax, a mammalian cell expression vector 
allowing the production of a His tagged BMP4 fusion protein. COS- 7 cells were then 
transfected with this expression vector under optimized conditions to produce fusion His-
mcBMP4 protein. Finally, the His- tagged fusion protein was purified from crude cell 
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lysate using a nickel-chelating affinity column. Although fusion protein expression was 
verified by Western Blot in the crude cell lysate, initially weak expression levels coupled 
with loss suffered during subsequent purification steps resulted in no detectable protein at 
the final stage of purification. In an alternative approach, an E.coli expression system 
was selected for protein expression and purification. A pGEX-KG vector carrying 
mcBMP4 insert with the correct reading frame was constructed. E.coli BL-21 cells were 
then transformed with this expression vector under optimized conditions to produce GST 
fusion protein, GST-mcBMP4. Subsequently, this fusion protein was purified using a 
GST affinity column and the expression of the fusion protein was verified by western blot. 
In the second direct production approach, cBMP4 peptide was first designed 
using bioinformatics' tools and synthesized by a commercial company. Mice were next 
immunized following a standard protocol and immunization schedule. Once a specific 
immune response in immunized mice had been verified, speenocytes were then harvested 
and fused with sp2/0 cells for monoclonal antibody production. Clones were 
subsequently screened for anti-cBMP4 specific monoclonal antibody production. 
Materials and Methods 
Mature Bone Morphogenetic Protein 4 Expression in Mammalian Cells 
Total chick RNA isolation. Two dozen fertilized eggs were bought from Olivera 
egg ranch (San Jose, CA), incubated for four days at 99±1°F with 100% humidity, and 
rotated automatically during the incubation in the egg chamber. Incubation times were 
extended to 4 days to correct for the temporary cessation of development that was found 
to occur as a result of temperature drop during commercial storage and transportation of 
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the eggs to the lab. At the end of incubation, chick embryos were harvested surgically, 
and immediately put into RNAlater solution (Ambion) to inactivate the Rnase activity as 
rapidly as possible. Net weights of the chicken embryos were obtained in these initial 
process steps. 
Chick total RNA was isolated using reagents supplied in Ambion's ToTALLY 
RNA™ Total RNA Isolation Kit (Cat#AM1910) and following the manufactures 
recommended protocol. Chicken embryos were transfered to a 50 ml conical tube 
containing lOx volume of Denaturing reagent (each mg of tissue represents about 1 ul of 
volume). Tubes were kept on ice and the tissue homogenized using a mechanical 
homogenizer and stainless steel rotor. The tissue lysate was collected, poured into screw-
capped polypropylene Sorval tubes and centrifuged at 12,000xg for 3-5 min at 4°C to 
pellet debris. Harvested supernatants were transferred into a 50 ml conical tube. The 
volume measured was defined as the starting volume. One starting volume of phenol: 
chloroform: isoamyl alcohol (25:24:1, PH 7.5) was then added to the lysate, the mixture 
vigorously vortexed for 1 min, incubated on ice for 15 min, and then centrifuged again at 
12,000xg for 15 min at 4°C. Following this centrifugation, the upper aqueous phase was 
harvested, its volume measured, and the solution transferred to a new 50 ml conical tube. 
An amount of Rnase free sodium acetate (3M, PH 4.5) equal to 1/9 th the volume of the 
transferred aqueous phase was added. The mixture was agitated for 10 seconds to create 
a homogeneous solution. Next, one starting volume of acid-phenol: chloroform (AP: C) 
was added to the adjusted aqueous phase. The solution was vortexed for 1 min, stored on 
ice for 15 min and then centrifuged at 12,000xg for 15 min at 4°C. The aqueous phase 
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was transferred to a new RNase-free polypropylene tube (with capacity at least twice the 
volume of this harvested aqueous phase) and the total RNA then precipitated by adding 
an equal volume of isopropanol with subsequent mixing. The RNA was allowed to 
precipitate overnight -20°C. After the incubation was complete, the preparation was 
centrifuged at 12,000xg for 15 min at room temperature. The supernatant was decanted 
off and the residual salts was removed by gently vortexing (washing) the pellet using 
freshly made 70% ethanol. RNA was recovered by centrifugation for 5-10 min at 3000xg 
at room temperature. The final RNA pellets were then resuspended in the desired volume 
of DEPC water containing 0.1 mM EDTA (100 (xl per 100 mg of starting material) and 
the material stored at -80°C until needed (White, 2004). 
PCR amplification of chick mature cBMP4. The entire coding region of cBMP4 
was amplified using gene specific primers according to the published cBMP4 sequence 
from GenBank (Accession number: X75915). Complete complementary primers were 
designed for blunt end ligation using Vector NTI (Invitrogen). Sense primer was 5' 
ATGATTCCTGGTAACCGAATGC3'; Antisense primer was 
5'AGGGAAGGGGTCAGCG 3'. The sense primer started at nucleotide #1 while the 
antisense primer started at nucleotide #1228. The total number of nucleotides amplified 
was 1228 bp. RT-PCR was employed using an OneStep RT-PCR kit from Qiagen (Cat# 
210210) to generate ds cDNA from chick total RNA under the standard conditions. 
RT-PCR reaction conditions were as follows: lx RT-PCR reaction buffer 
(containing 15mM MgCb), dNTP mix 0.2 mM each, primer 0.6 uM each, 1.3 ug chick 
total RNA and 1 unit of enzyme mix in a 50 ul reaction volume. RT-PCR amplification 
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was carried out at 50°C for 30 min, 95°C for 15 min followed by 40 cycles of 94°C for 30 
Sec, 65.9°C for 1 min, 72°C for 1 min, and a final extension at 72°C for 10 min. 
The mature region of cBMP4 was amplified using gene specific primers 
(complete complementary) designed for blunt end ligation using Vector NTI (Invitrogen). 
Sense primer was 5'AGCCCCAAGCACCACGGTTC3'; Antisense primer was 5' 
GGGAAGGGGTCAGCGGCAC3'. The sense primer started at nucleotide #874, while 
the antisense primer started at nucleotide #1219. The total number of nucleotides 
amplified was 354 bp. Standard PCR was employed to amplify the mcBMP4 using the 
full length cBMP4 PCR product as template. Taq PCR Core Kit from Qiagen (Cat# 
201223) was used to set up PCR reaction following manufactures instructions. 
PCR reaction conditions were as follows: lx PCR reaction buffer (containing 15 
mM MgCl2), dNTP mix 0.2 mM each, primer 0.5 uM each, 100 ng cBMP4 PCR product 
and 1 unit of Taq polymerase in a 50 ul reaction volume. PCR amplification was carried 
out at 94°C for 3 min, followed by 30 cycles of 94°C for 30 sec, 62°C for 1 min, 72°C for 
1 min, and a final extension at 72°C for 10 min. 
Subcloning of mature cBMP4 gene into a mammalian cell expression vector. The 
pcDNA4/HisMax mammalian cell expression vector from Invitrogen (Cat # V864-20) 
was selected to produce recombinant mcBMP4. Major features of this vector includes a 
CMV promoter for high level expression in a wide range of mammalian cells, a QBI 
SP163 translational enhancer for increased levels of recombinant protein expression, an 
N-terminal peptide encoding the Xpress™ epitope, a polyhisidine metal-binding tag, and 
an enterokinase recognition site for tag removal. 
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The expression vector was first linearized using Kpnl restriction enzyme and 
repurified. The linearized vector was next given blunt ends by treatment with T4 DNA 
polymerase (New England Biolab, cat# M203S) and reaction buffer at 12°C for 20 
minutes. The blunt end reaction contained lx T4 DNA polymerase buffer, 100 ug/ml 
BSA, 0.1 mM each dNTP mix, 0.3 unit of T4 DNA polymerase and 1 pmole of Kpnl 
digested vector in a 50 ul reaction. The digested vector was then treated with Aquatic 
Phosphotase (New England Biolab) for 15 minutes at 37°C to generate dephosphorylated 
ends. The dephosphorylation reaction contained lx aquatic buffer, 1 unit of Aquatic 
Phosphotase and the previously end-converted vector in a 50ul reaction. 
The amplified mature cBMP4 PCR product was ligated into the linearized and 
dephosphorylated blunt ended expression vector. The ligation reactions were performed 
according to Novagen's protocol described in pST Blue Perfectly Blunt Cloning kit (Cat# 
70191). The plasmid constructs were transformed into NovaBlue Singles competent cells 
(part of Perfectly Blunt Cloning kit) according to the manufacturer's protocol. Cells were 
plated into IPTG (0.5mM)/Xgal (80 ug/ml)/Amp (100 ug/ml)/LA plates, grown 
overnight at 37°C, and white colonies were picked and subcultured into a gridded LA 
plate and incubated overnight. Next day, 10 colonies were picked to perform colony 
PCR for the purpose of identifying the colonies carrying the desired cBMP4 insert. 
Colony PCR reaction conditions were as follows: lx PCR reaction buffer (containing 15 
mM MgCb), dNTP mix 0.3 mM each, primer 1.5 uM each, lOul cell lysate and 1 unit of 
Taq polymerase in a 25 ul reaction volume. PCR amplification was carried out at 94°C 
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for 3 min, followed by 30 cycles of 94°C for 30 sec, 62°C for 1 min, 72°C for 1 min, and 
a final extension at 72°C for 10 min. 
A colony carrying the mature cBMP4 insert was selected, cultured using LB broth 
with 50 ug/ml Ampicillin, and grown with shaking at 225 rpm overnight at 37°C. 
Plasmid DNA was isolated the following day according to Qiagen's minielute kit 
protocol. Plasmid concentration was determined using Nanodrop and sent out to Gene 
Gateway (Hayward, CA) for DNA sequencing using both T7 (flanking the insert 
upstream) and BGH primers (flanking the insert downstream) to confirm both the 
orientation and nature of the insert. 
Culture ofCOS-7 cells for transfection. COS-7 cells were purchased from 
American Type Culture Collection (ATCC, Manassas, VA). The complete medium used 
for culturing the cells was DMEM supplemented with L-gultamine, penicillin-
streptomycin, and 10% heat-inactivated fetal calf serum (FCS). A total of 2X10 5 cells 
were seeded in a Falcon 25 cm2 tissue culture flask with 12 ml culture medium, and the 
cells were incubated in a 37 °C incubator with 5% CO2 and 99% humidity. The cells 
were examined daily using inverted microscope to ensure healthy growth and no 
contamination. Every 2-3 days, cells were subcultured at the ratio of 1:4 by standard 
trypsionization (White, 2004). The old medium was removed followed by rinsing the 
cells with pre-warmed PBS. Then the adherent cells were detached from the bottom of 
the flask by 2 ml 0.2% (W/V) trypsin-EDTA (1 mM) treatment about 5 min at 37°C. 
After the cells were detached, 6 ml of complete medium were added to inactivate the 
trypsin. Four new flasks containing 7 ml of the fresh medium were prepared. A 2 ml 
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volume of cell suspension was transferred to each new flask, and incubated in the CO2 
incubator. 
COS-7 cells transfection condition optimization. In order to access the 
transfection efficiency, pcDNA/HisMax/lacZ plasmid from Invitrogen (part of 
pcDNA4/HisMax mammalian cell expression vector) was used as positive control to 
optimize the transfection condition based on the /J-galactosidase expression. Mock-
transfected cells in absence of any DNA were also used as negative control to provide 
protein background. 
COS-7 cells were transiently transfected using lipofectamine 2000 reagent 
(Invitrogen) following the manufacture instructions. One day before transfection, cells 
were passaged as described earlier and counted using Trypan Blue dye and a 
hemocytometer. A total of 5x105 cells in 2 ml growth medium without antibiotics was 
seeded on a cover slip (10cm2 surface area) placed in a 6- well plate so that cells would 
be 90-95% confluent at the time of transfection. The medium used for transfection was 
Opti-MEM I Reduced Serum Medium (Invitrogen), with L-glutamine added to Opti-
MEM I prior to use. Antibiotics and serum lower the transfection efficiency by either 
disturbing the cells or interfering with the liposome mediated mechanism of DNA 
transfer. Therefore, an hour before transfection, complete medium was removed, and the 
cells rinsed with CMF-PBS to remove the trace of serum-containing medium. Finally, a 
total of 2 ml Opti-MEM I was added to each well, and the incubation was continued. 
For each transfection sample, the complex was prepared using a DNA mass to 
Lipofectamine 2000 volume ratio of 1 (ug): 2.5(ul) or 1 (ug): 3 (ul) to optimize the 
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transfection. For a DNA to Lipofectamine ratio of 1:2.5, DNA sample was prepared by 
diluting 4 ug of pcDNA/HisMax/lacZ into 250 ul of Opti-MEM I medium. For a DNA 
to Lipofectamine ratio of 1:3, DNA sample was prepared by diluting 3 ug of 
pcDNA/HisMax into 250 ul of Opti-MEM I medium. In another tube, 10 ul 
lipofectamine reagent were mixed with 240 ul of Opti-MEM I for 1:2.5 DNA to 
lipofectamine ratio. Nine microliter of Lipofectamine reagent was mixed with 240 ul of 
Opti-MEM I for 1:2.5 DNA to lipofectamine ratio. After 5 minutes incubation of 
lipofectamine-Opti-MEM I reagent, the lipofectamine and DNA solution were combined, 
mixed gently and incubated for 20 minutes at room temperature to allow for the 
formation of liposome-DNA complexes. Finally, 500 ul Opti-MEM I was removed from 
each well, and replaced by 500 ul of lipofectame-DNA complex solution. The plate was 
returned to incubator to incubate for 4-6 hours. Following incubation, the medium was 
removed totally and complete medium were added. Cells were incubated continuously 
and observed for transient expression over 5 days. In addition to a positive control, 
mock- transfected cells were also used as a negative control. 
Staining cells for /3-galactosidase activity. At the end of incubation, cells were rinsed 
twice with sterile CMF-PBS, then fixed by adding 2 ml glutaraldehyde solution (0.25% 
v/v in CMF-PBS) and incubated at room temperature for 15 minutes. Cells were rinsed 
again three times with 5 ml CMF-PBS to remove residual glutaraldehyde. Finally, 2 ml 
X-Gal Working Solution (0.2% w/v X-Gal in CMF-PBS supplemented with 2 mM 
MgCl2, 5 mM K4Fe (CN) 6-3H20 and 5 mM K3Fe (CN) 6 was added to each well and 
incubated 20 minutes. At the end of the staining period, X-Gal solution was removed and 
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CMF-PBS was added for better viewing of the stained cells. Stained cells were observed 
under the inverted microscope and images recorded using a Nikon model digital camera. 
Preparation of cell extracts. At 48 hour post transfection, cells were rinsed with 
PBS and harvested in 1 ml PBS using a rubber cell scraper. The harvested cells were 
transferred into a 15 ml conical tube and centrifuged at 1500xg for 5 minutes. The 
supernatant was discarded, and the pellet was resuspended in 2 ml cell lysis buffer 
containing 1% Nonidet P-40, 150 mM NaCl, and 50 mM Tris-HCl at PH 7.8. A 
mammalian tissue protease inhibitor cocktail containing AEBSF, Aprotinin, Bestatin 
hydrochloride, E-64, EDTA and Leupeptin hemisulfate salt (Sigma) was also added to 
the cell suspension to prevent protein degradation by endogenous enzymes. The cell 
suspension was incubated on ice for 15 min. Following the incubation, the cells were 
further lysed by two freeze-thaw cycles using liquid nitrogen and 42°C water bath. Cells 
were then sonicated using Sonifier Cell Disruptor model 350, set at 50% duty cycle and 
power output setting of 5.5 for 5 cycles with 20 s burst and 40 s cooling period for each 
cycle. After lysis, the cell lysate was centrifuged at 1500xg for 10 min. Then the 
supernatant containing cell extract was collected and stored at -80°C. 
Protein purification using Probond™ purification system. The fusion protein had 
six tandem histidine residues on its N- terminus, and this polyhistidine tag has a high 
affinity for a resin containing nickel ions. Therefore, when the tagged protein was 
applied to a pre-filled ProBond™ column with ProBond™ nickel-chelating Resin 
(Invitrogen, Cat# K850-01), it was captured by the column's nickel-chelating resin. The 
fusion protein was later eluted with an imidazole gradient under native conditions. 
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Imidazole has a similar structure to that of histidine and can thus desorb tagged protein 
from the column by competitive substitution. All the buffers used in the system had a pH 
of8. 
The purification of the His-mcBMP4 fusion protein was performed according to 
the manufacturer's protocol, hi brief, 2 ml of nickel-chelating resin was poured into a 10 
ml purification column and allowed to settle completely by gravity. The supernatant was 
gently removed by aspiration and the column pre-equilibrated by washing twice with 6 
ml sterile distilled water and three times with 6 ml Native Binding Buffer (20 mM 
sodium phosphate and 500 mM sodium chloride, pH 8). Prior to loading, 5ml of the 
concentrated cell extract was raised to 8 ml by adding Native Binding Buffer. Following 
this dilution step, the sample was applied to the column and mixed with the resin for 60 
min at room temperature with gentle agitation to keep the resin suspended in the lysate 
solution. After the 60 min incubation, the column was washed twice with 8 ml Native 
Binding Buffer and three times with 8 ml Native Wash Buffer (20 mM imidazole, 20 mM 
sodium phosphate and 500 mM sodium chloride, pH 6) to remove non-binding and/or 
low affinity non-specifically bound protein. Following this washing step, the fusion 
protein was eluted with 10 ml Native elution buffer with an imidazole gradient. The 
gradient was generated by applying four elution buffers (pH6) in increasing imidazole 
concentration (50 mM, 200 mM, 300 mM, and 500 mM) into the column. The eluented 
fraction was collected from the column and each fraction was analyzed with SDS-PAGE. 
Western blot analysis. A 4-12% Bis-Tris gradient NuPage minigel (Invitrogen) 
was used to verify the efficiency of protein purification. A western blot was then used to 
22 
verify the presence of recombinant His- mcBMP4 fusion protein. Each sample was 
diluted using 4x sample buffer (Invitrogen) and heated at 70°C for 10 min. The samples 
were cooled and quickly centrifuged to remove insoluble derbies and loaded into each 
wells of the gel. MES-SDS buffer (50 mM MES, 50 mM Tris base, 0.1% SDS, 1 Mm 
EDTA pH 7.3) was used as the running buffer. The gel was run at a constant 200 v for 
35 min. Following electrophoresis, the proteins separated in the SDS-PAGE gel were 
electrophorically transferred to a PVDF membrane (pre-wet in methanol). The XCell II 
blot Module apparatus was assembled according to manufacturing protocol and the 
transfer was conducted at a constant 30 V for 1.5 hour using NuPAGE transfer buffer (25 
mM bicine, 25 mM bis-Tris, 1 mM EDTA PH 7.2). After the transfer, the gel was 
exposed to Coomassie blue stain for overnight to evaluate the transfer efficiency. The 
membrane was stained in Ponceau S solution containing 0.5% (w/v) Ponceau S and 1% 
(v/v) glacial acid for 10 min, and then rinsed with DI water. 
To develop the immunoblot, the PVDF membrane was placed in blocking buffer 
(pH7.4) for 1 hour at room temperature. The blocking buffer was prepared by adding 2 g 
of BSA to a liter of PBS containing 0.05% Tween 20. The membrane was then incubated 
with primary antibody (anti-Xpress antibody, a mouse monoclonal IgG from Invitrogen) 
diluted 1:5000 in blocking buffer at 37°C for 2 hours. The primary antibody directed 
against the Xpress epitope was removed after one hour, and the blot washed with 
blocking buffer 5 times over 30 min. After washing, the membrane was incubated with 
the secondary antibody (rabbit anti-mouse IgG-AP conjugate, Sigma) diluted 1:5000 in 
blocking buffer for 1 hour at room temperature. After incubation, the membrane was 
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washed 3 times with blocking buffer and twice with PBS/Tween 20 over 30 min. Finally, 
the membrane was rinsed with water and developed using the BCIP/NBT-substrate 
(SIGMA FASTA BCIP/NBT Cat# B5655) for 5 min. After developing, the membrane 
was washed in DI water and then air-dried. 
Mature cBMP4 Protein Expression in E.coli 
Subcloning mature cBMP4 into a bacterial expression vector. The mature region 
of cBMP-4 was also amplified using gene specific primers designed by Vector NTI 
software (Invitrogen). Sense primer was 5' 
CGAAGGATCCAGCCCCAAGCACCACGGTTCCC 3'. Antisense primer was 5' 
AACAAAGGATCCGTCAGCGGCACCCGCACCCCTC 3'. The sense primer started at 
nucleotide #874, while the antisense primer started at nucleotide #1219. The total 
number of nucleotides amplified was 370 bp. Standard PCR was employed to amplify 
the mature cBMP4 using the full length cBMP4 PCR product by Qiagen's Taq core kit. 
PCR reaction conditions were as follows: lx PCR reaction buffer (containing 15 mM 
MgCl2), dNTP mix 0.2 mM each, primer 0.5 uM each, 100 ng cBMP4 PCR product and 
1 unit of enzyme mix in a 50 ul volume. RT-PCR amplification was carried out at 94°C 
for 3 min, followed by 30 cycles of 94°C for 30 sec, 67.5°C for 1 min, 72°C for 1 min, 
and a final extension at 72°C for 10 min. 
The expression vector pGEX-KG was kindly provided by Dr. Soto. Major 
features of this vector include a Glutathione S-transferase (GST) fusion tag and a 
thrombin cleavage site. Since GST is highly soluble, recombinant protein fused with 
GST tag could increase solubility. In addition, GST processes enzymatic activity. The 
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level of fusion protein expression could be estimated by detecting GST activity. 
Thrombin cleavage site is located right after GST for the convenience of tag removal. 
The vector was digested using BamHI, then dephosphorylated using Aquatic 
phosphatase to prevent vector religation. The mcBMP4 PCR product, also digested using 
BamHI, was then ligated to the vector according to Novagen's protocol described in pST 
Blue Perfectly Blunt Cloning kit, and transformed into E.coli (BL-21) competent cells 
(Stratagene) according to manufacturer's protocol. Cells were plated into LA /Amp (100 
)ig/ml) plates and grown overnight at 37 °C. The next day, 10 colonies were picked to 
perform colony PCR for the purpose of identifying the colonies carrying the desired 
cBMP4 insert. A colony carrying what appeared to be mcBMP4 insert was selected, 
cultured using LB broth with 50 p.g/ml Ampicillin, and grown with shaking at 225 rpm 
overnight at 37°C. Plasmid DNA was isolated the following day according to Qiagen's 
minielute kit. Plasmid concentration was determined using Nanodrop and sent out to 
Sequetech (Montain view, CA) for DNA sequencing using both pGEX3 and pGEX5 
primers. 
Screening PGEX recombinant for fusion protein expression. Several colonies of 
E.coli transformed with the pGEX recombinants were picked for inoculation into separate 
tubes containing 2 ml 2xYTA medium containing 16 g/L trytone, 10 g/L yeast, 5 g/L 
Nacl and 100 ug/ml Ampicillin. The liquid culture was grown to an OD 6oo of 0.6-0.8 
with vigorous agitation at 37°C. Cells were induced for two hours by adding 20 ul 100 
mM isopropyl-(8-D-thiogalactoside (IPTG) (final concentration ImM), and the liquid cell 
culture was then centrifuged at 500xg for 5 min. The cells were spun down and lysed 
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using sonication in 10s burst with 20s rest. The crude cell lysate was centrifuged for 10 
min at 7000xg again to remove insoluble material. The supernatant was harvested and 
added into 50% slurry of Glutathione Sepharose 4B pre-equilibrated in ice cold PBS (pH 
7.3). After 30 min incubation, sample was spun down again at 500xg for 5 min to 
sediment Glutathione Sepharose 4B with recombinant protein attached. PBS (pH7.3) was 
used to wash the sample three times. The fusion protein was eluted with elution buffer 
(pH 8.0) containing 50 mM Tris-HCl, 10 raM reduced Glutathione. The eluted fraction 
was analyzed by 4-12% pre-casted No vex NuPAGE gel (Invitrogen). 
Fusion protein expression optimization. After the candidate expressing 
recombinant protein was selected, important factors such as growth temperature and 
induction conditions have been evaluated to achieve optimal protein expression. 
A selected candidate colony was subcultured overnight at 37°C. Several colonies 
were picked and transferred into separate tubes containing 40 ml 2xYTA medium. Cells 
were cultured either at 30°C or 37°C until its OD 6oo reached about 0.6-0.8. Five different 
IPTG concentrations (0.1 mM, 0.25 mM, 0.5 mM, 0.75 mM and 1 mM) were added into 
the liquid culture, and the cells were induced for different time period (2 hours, 4 hours, 6 
hours, 8 hours and 10 hours). After induction, cells were lysed by sonication as 
previously indicated. The supernatant was harvested and the relative level of GST fusion 
protein expression was analyzed by GST activity using CDNB (l-chloro-2, 4-
dinitrobenzene) as the substrate. The CDNB solution contains 0.1 mM KH2PO4 (pH 6.5), 
ImM CDNB and ImM reduced glutathione. Eight hundred microliter of CDNB was 
transferred into one UV-transparent cuvettes containing 50 ul of the cell lysate 
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supernatant and the absorbance was measured at 340 nm at 1 min invervals for 5 min. 
A34o/min/ml was calculated as a value to indicate relative GST fusion protein content. 
AA34o/min/ml= [A340 (t2)-(ti)]/ (t2-ti) (ml sample added), where A340 (t^) =absorbance at 
340 nm at time t2 in min. (ti) =absorbance at 340 nm at time ti in min. 
Mature cBMP4 protein expression and purification in E.coli. After the 
expression condition was optimized, 100 ml of cells (2 liter cells for large scale) were 
grown and induced at the optimized condition. Cell pellets were collected and sonicated 
as previously described for small scale protein expression in 100 ml. Cells were lysed 
using Bug Buster reagent (Novagen, Cat# 70584) supplemented with 0.1 raM PMSF 
solution for large scale protein expression in 2 liter. A crude cell lysate was purified 
using Glutathione Sepharose 4B beads as described above. Western Blot analysis was 
employed to verify the expression of fusion protein. The detailed procedures were 
described in previous section. The primary antibody was rabbit anti- GST polyclonal 
antibody from GE health care at a 1:1000 dilution. The secondary antibody was goat 
anti-rabbit IgG-HRP polyclonal antibody from Sigma at a 1:2000 dilution. 
Monoclonal Antibody Production Using Synthetic Peptide 
Selection of synthetic peptides. The complete sequence of chick BMP4 was 
obtained from the protein sequence database of the National Center of Biotechnology 
Information (http://www.ncbi.nlm.nih. gov/). The antigenic region of the mature cBMP4 
protein was analyzed using the Protean function (protein structure analysis & prediction) 
of the Lasergene software from DNASTAR to predict the peptide's secondary structure, 
hydrophilicity, surface availability and antigenicity. In addition, the amino acid sequence 
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of cBMP4 was also submitted to Alpha Diagnostic International (San Antonio, TX) for 
an independent antigenicity analysis. 
To ensure that the selected regions were unique to chick BMP4 rather than 
common family member, the complete mcBMP4 amino acid sequence was compared to 
the sequence of its closest family member (chick BMP2) and BMP4 sequences in two 
other species (human and mouse). The amino acid sequences of mouse BMP4, human 
BMP4, chick BMP4, mouse BMP2, Human BMP2 and chick BMP2 were imported into 
Biology Workbench (http: //seqtool.sdsc.edu/CGI/BW/cgi) from the protein sequence 
database. One peptide sequence SPKHHGSRKNKKNCRRH was selected for synthesis. 
Manufacture of synthetic peptides. Chick BMP4 peptide was manufactured by 
Alpha Diagnostic International (San Antonio, TX). Ten milligram of cBMP4 peptide 
(average mass: 2071.0 g/mole) was synthesized at 100% purity. Six milligram of cBMP4 
peptide was coupled to 3 mg of keyhole limpet hemocyanin (KLH) using glutaraldehyde 
(GLUT) coupling method. A cBMP4 -KLH conjugate was supplied as 2 mg/ ml solution 
in PBS and stored in 0.3 ml aliquots at -70 °C. The remaining 4 mg of unconjugated 
cBMP4 peptide was supplied in a powder form and stored at -70 °C. 
Animals. Female BALB/C mice were purchased and taken cared by University 
Animal Care (UAC) Personnel according to approved guidelines in IACUC (Institutional 
Animal Care and Use Committee) protocol No.867 (Appendix 1). 
Mice immunization for screening assay. Three mice were immunized with 
cBMP4-KLH conjugated peptides following the immunization schedule (Table 1). In 
brief, one hundred microgram conjugated peptides in complete Freund's adjuvant (CFA) 
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(0.3 ml) from Sigma were injected into each mouse via Intraperitoneal (IP) routes for the 
first immunization. One hundred microgram conjugated peptides in incomplete Freund's 
adjuvant (IFA) (0.2 ml) from Sigma were injected into each mouse subcutaneously (SC) 
for the second immunization. One hundred microgram conjugated peptides only (0.2 ml) 
were injected into each mouse subcutaneously for the third and fourth immunization. 
Blood samples were collected as indicated by UAC personnel. Blood samples were 
combined and allowed to stand at room temperature for 20 min to allow the clot to form, 
and then samples were centrifuged for 10 min at 12,000rpm to prepare serum. After the 
immune response has been verified by ELIS A, mice were primed with 0.1 ml pristine 3 
days before injection of SP2/0 mouse myeloma cells. Then 1X106 SP2/0 cells (in 0.2 ml 
PBS) were injected into mouse abdomen via IP route. A week later, mice ascites were 
harvested. Mice which exhibited moderate abdominal distention, lack of appetite, pale 
skin and an increase of respiratory effort were induced to narcosis using carbon dioxide 
and cervically dislocated under supervision of ACF staff. Ascites was withdrawn using 
an 18 gauge needle post -mortem by peritoneal cavity tapping. Ascites samples from 
three mice were pooled together for optimizing the screening assay. 
Screening assay optimization and antibody specificity analysis by ELISA. 
Screening of specific antibody producing hybridomas is a very critical step since the 
success of this project is largely dependent on a reliable screening assay for estimating 
the immune response of the mice and selecting antibody producing hybridoma cells. The 
amount of antigen required to coat each plate and the dilution of primary immune serum 
and secondary antibody thus needed to be optimized. 
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The specificity of the antiserum was analyzed by ELISA using the following 
protocol. Polystyrene 96-well plates (Nalgene Nunc International, Rochester) were 
coated with cBMP4 peptides in PBS solution (lOug/ml) overnight at room temperature. 
The next day, the peptide solution was discarded and the blocking buffer containing 10% 
skim milk in water was added into each well. The plate was blocked at room temperature 
for one hour. After 1 hour blocking reaction, the plate was washed three times using PBS 
with 0.05% Tween. Half of the plate was then incubated with 100 ul of different 
dilutions of immune or pre-immune sera for one hour at room temperature, while the 
other half of the plate was incubated with 100 ul of different dilutions of immune sera 
pre-absorbed with 500 ng antigenic cBMP4 peptide. After incubation, wells were 
washed again three times and treated with 100 ul horse radish peroxidase (HRP) 
conjugated rabbit anti-mouse IgG (Sigma) at 1:500 dilution for one hour at room 
temperature. Next, the wells were washed five times and incubated with 0.1 M 3, 3', 5, 
5'-Tetramethylbenzidine (TMB) (Sigma). The absorbance value at 405 nm was then 
measured using an automatic ELISA plate reader. 
Table 1. Mice immunization schedule for screening assay 
Week Procedure 
1 Preimmune blood sample 
o 
1 antigen/ adjuvant injection (1:1 antigen in CFA, 0.3 ml IP) 
3 2° antigen/ adjuvant injection (1:1 antigen in IFA, 0.2 ml SC) 
5 3 antigen/ adjuvant injection (antigen in saline, 0.2 ml SC) 
7 4 antigen/ adjuvant injection (antigen in saline, 0.2 ml SC) 
Immune blood sample collection 
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Cell fusion for monoclonal antibody production. After the specificity of the mice 
immune response to cBMP4 peptides were verified by ELISA, three mice were 
immunized again following the protocol indicated above. After the immune response has 
been verified by ELISA, two mice showing the strongest immune response were 
sacrificed by cervical dislocation, and their spleens were harvested in a sterile manner. 
The spleen was gently dissociated mechanically by pressing the tissue against a sterile 
nylon screen and the spleenocytes were isolated by layering the cell suspension onto 10 
ml Ficoll density medium. Cells were then centrifuged cells at 600xg for 20 min in Ficoll 
density medium. Approximately 1x10 of the isolated spleenocytes were fused with 
lxlO7 SP2/0 cells in 50% polyethylene glycol (PEG) fusion medium slowly. The fused 
cells were then transferred into hypoxanthine aminopterin thymidine (HAT) medium and 
aliquoted into several 96-well tissue culture plates and incubated at 37° C. Hybridomas 
were screened one week after cell fusion by ELISA. 
Results 
Bone Morphogenetic Protein 4 Expression in Mammalian Cells 
Total chick RNA isolation. Total RNA was isolated from chick embryos using 
Ambion's Total RNA system. The concentration of total RNA was determined by 
measuring RNA's absorbance at 260 nm (OD260 nm). The purity of total RNA was also 
estimated by measuring the ratio of UV absorbance at 260& 280 nm. Finally, the 
integrity of total RNA sample was evaluated by 2% agarose gel electrophoresis. From 12 
chick embryos (about 1.5 g), 9.2 mg total RNA (680 |il) was isolated with a 
concentration of 13.67 ug/ul From gel analysis (Figure 1), the total chick RNA was 
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Figure 1. Analysis of different amounts of total RNA isolated from day 4 chick 
embryos using 2% agarose gel electrophoresis. Samples were run in TAE buffer at 
100V for 60 min using 2% of E- gel. Lane 1= 3 ug total RNA; Lane 2= 2 ug total 
RNA; Lane 3= 1 ug total RNA. Lane 4= lkb MW ladder. 
1228bp 
354bp 
Figure 2. Gel Analysis of cBMP4 inserts amplified from chick total RNA using PCR. 
Samples were run in TAE buffer at 100V for 60 min using a 1% agarose gel. Panel A 
shows the amplified cBMP4 insert containing the entire open reading frame. Lane 1= 
1228 bp cBMP4 insert containing the entire open reading frame; Lane 2= lOObp size 
ladder; Lane 3= High MW mass standard. Panel B shows the amplified cBMP4 insert 
containing only the mature region of the cBMP4 DNA sequence. Lane 1= 354 bp 
mcBMP4 insert containing the mature region (874bp-1227 bp) of the cBMP4 sequence; 
Lane2= lOObp size ladder; Lane 3= Low MW mass standard. 
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intact since the 28s, 18s and 5s rRNA bands were distinctive without degradation. The 
RNA sample appeared relatively free of protein contamination since the 
OD260nm/OD280nm ratio was 2.08. 
PCR amplification ofcBMP4 entire coding region and mature region. A 1228bp 
cBMP4 sequence was amplified from chick total RNA using RT-PCR (Figure 2A) and 
ligated into Novagen's blunt end cloning vector pSTBlue-1 for storage in the long term. 
In the mean time, mature cBMP4 was also amplified using 1228 bp cBMP4 PCR product 
as template. The amplified mature cBMP4 insert with 354 bp length containing the 
region from 874 bp-1227 bp of the cBMP4 sequence was indicated in Figure 2B. 
Subcloning of mature cBMP4 gene into a mammalian cell expression vector. The 
mature cBMP4 inserts were ligated into pretreated blunt ended expression vector 
cDNA4/HisMax. After transformation of the constructed expression vector, cells grown 
on the LA/AMP plates were selected to perform colony PCR using gene specific primers 
in order to identify the colonies carrying the desired mcBMP4 insert. Gel analysis of 
colony PCR products of individual E. coli clones indicated that all clones contained the 
desired mcBMP4 inserts (Figure 3). In order to confirm the sequence and orientation of 
the cBMP4 inserts, plasmids were isolated from three clones and sent out for DNA 
sequencing. 
A Blast search within the Genebank NCBI database confirmed the identity of the 
inserted DNA sequence to be chick mature BMP4 and the mcBMP4 was ligated in the 
correct orientation with the pcDNA/HisMax vector (Appendix 2). 
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The partial DNA sequencing chromatogram of the pcDNA/HisMax-mcBMP4 construct 
contained the first 24 bp of mature chick BMP4 sequence from nucleotide 287 to 
nucleotide 310 (red underline) that ligated in frame with the enterokinase recognition 
sites (yellow highlighted region). The arrow indicates the junction site between 
mcBMP4 sequence and vector enterokinase recognition sequence, which further 
indicated that the recombinant protein has the correct reading frame and orientation. The 
DNA sequence (nucleotide 263 to nucleotide 286) underscored with blue dash line was 
the Xpress Epitope, which can be recognized by anti-Xpress antibody to facilitate 
recombinant protein identification (Figure 4). The full pcDNA/HisMax-mcBMP4 
construct DNA sequencing chromatogram was indicated in the Appendix 3. 
COS-7 cells transient expression condition optimization. COS-7 cells were 
transfected transiently using pcDNA/HisMax/LacZ control vector at two different 
Lipofectimin/DNA ratios (1:2.5 vs 1:3). In addition, the level of/3-galactosidase protein 
expression was estimated using X-gal staining for five continuous days (Figure 5). /3-
galactosidase expression reached about 30% after 24 hour of transfection (Figure 5 A), 
and then the maximum level of expression was achieved after 48 hours of transfection, 
which was about 95% cells expressing /3-galactosidase (Figure 5 B). From day 3, protein 
expression level decreased dramatically to about 20% (Figure 5 C), and almost 
disappeared after day 4 (Figure 5 D-E). /3-galactosidase expression was not detected in 
mock transfected cells (Figure 5 F). Because of the decline of protein expression after 48 
hours, transient expression condition at two different Lipofectmine/DNA ratios was 
optimized only at day two. There is no remarkable difference in terms of protein 
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Figure 3. Gel analysis of colony PCR products of individual E. coli clones 
carrying the mcBMP4 insert. All clones contained the desired inserts. 
pcDNA4/HisMax expression vector was used to clone mcBMP4 gene for 
mcBMP4 expression in COS-7 cells. Colonies were boiled for 10 min and 10 JU.1 
cell lysate were used for colony PCR. Lane 1= 100 bp DNA ladder; Lane3-12 = 
PCR products of selected individual E. coli clones. 
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25C 26C- 270 280 2SC 800 310 
aGCAMIGGGTCGGGATCTGTACGACGATSACSATAASAGCCCOkAGCACCACGGTTCCCGC 
• 1 • -
Figure 4. Partial DNA sequencing chromatogram of pcDNA4/HisMax-
mcBMP4 construct. Red underline: mcBMP4 DNA sequence; Yellow 
highlight: EK recognition site; Blue dash line: Xpress epitope. Arrow 
indicates the ligation site of mcBMP4 insert with the pcDNA4/HisMax 
vector sequence. 
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Figure 5. X-Gal staining of COS-7 cells to optimize transient expression 
conditions. COS-7 cells were transfected transiently using pcDNAHisMax/LacZ 
control vector and different Lipofectamine/DNA ratios. /3-gal expression was 
monitored over 5 days. Panel A-E: cells expressing /3-gal from day 1 to day 5 
post-transfection using a Lipofectamine/DNA ratio of 3:1; Panel F: mock 
transfected cells without /3-gal expression. Panel G-H: Comparison of transient 
transfection efficiency using two different Lipofectamine/DNA ratios at day 2. 
Lipofectamine/DNA =2.5:l(PanelG). Lipofectamine/DNA =3:1 (Panel H). 
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expression level by varying lipofectamine vs DNA ratio (Figure 5 G-H). 
Lipofectamine/DNA ratio of 2.5:1 was chosen to conduct transfection using constructed 
expression vector pCDNA4/HisMax_mcBMP4. 
Mature cBMP4 protein expression and purification. After the transient 
transfection condition had been optimized and the transfection efficiency verified by the 
jS-gal staining assay, Cos-7 cells was transfected with the pcDNAhismax-mcBMP4 
plasmid. Crude cell lysate was purified using the ProBond™ purification system, and 
each elution fraction was examined for the presence of recombinant protein via Western 
Blot (Figure 6). The predicted MW of mcBMP4 is about 12.8 KD, while the N terminal 
peptide containing the Xpress epitope and the polyhistidine tag will add approximately 
3.4 KD to the mcBMP4 protein. The total MW of the recombinant mcBMP4 protein is 
thus approximately 16.2 KD. The western blot analysis showed that only the crude lysate 
fraction (lane 1) and the flow-through fraction (lane 11) contained any detectable 
recombinant mcBMP4 protein. No detectable recombinant protein was present 
either in the wash fraction (lanes 2-4) or elution fraction (lanes 6-10). 
Mature cBMP4 Protein Expression in E.coli 
Subcloning of mature cBMP4 into a bacterial expression vector. Mature cBMP4 
was also amplified using 1228 bp cBMP4 PCR product as template. The 370 bp mature 
cBMP4 amplification product contained the region from 874 bp-1219 bp of the cBMP4 
sequence and a linker region with BamHI sites (Figure 7). The mature cBMP4 insert was 
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Figure 6. Detection of recombinant mcBMP4 protein expression in COS-7 
cells using a 1:5000 dilution of anti-Xpress mAb by western blot. 
Recombinant mcBMP4 was purified using a nickel chelating affinity column 
and eluted with different concentrations of imidazole. Lane 1= crude lysate; 
Lane 2-4= three individual wash fractions. Lane 5= MW standard; Lane 6-
10= elution fraction with 50 mM, 200 mM, 300 mM and 500 mM imidazole 
respectively. Lane 11= flow through fraction. 
370 bp 
Figure 7. Gel analysis of mcBMP4 inserts amplified by PCR from 1228 bp 
cBMP4 DNA for cloning in pGEX-KG E.coli expression vector. Lane 1= 100 bp 
DNA ladder; Lane 2 and lane 3= 370 bp amplified mcBMP4 inserts containing 
Bam HI site for cloning in pGEX-KG vector. 
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then ligated into the Bam HI digested E.coli expression vector pGEX-KG. After 
transformation of the constructed expression vector, cells grown on the LA/AMP plates 
were selected to perform colony PCR using gene specific primer in order to identify the 
colonies carrying desirable mcBMP4 insert. From ten randomly selected clones, only 
one clone (clone 10) contained the 370 bp mcBMP4 insert (Figure 8). In order to confirm 
the identity and orientation of the mcBMP4 insert, pGEX-KG-mcBMP4 plasmids were 
isolated and sequenced. Blast search within Genenbank confirmed the identity of the 
inserted DNA sequence to be mcBMP4 and the mcBMP4 was ligated in the correct 
orientation with the pGEX-KG vector (Appendix 4). The partial DNA sequencing 
chromatogram of pGEX-KG-mcBMP4 construct indicated that the first 63 bp of the 
mature chick BMP4 coding region (from nucleotide 874 to nucleotide 936, red underline ) 
was ligated in frame with the Bam HI linker site (yellow highlighted region) in the pGEX 
Vector (Figure 9). The full pGEX-KG-mcBMP4 construct DNA sequencing 
chromatogram was indicated in the Appendix 5. 
Screening PGEX recombinants for fusion protein expression. Clone 10 was re-
streaked and five clones (Al through A5) were chosen as the potential candidates for 
GST-mcBMP4 fusion protein screening assay. The predicted MW of mcBMP4 is about 
12.8 KD, while the N- terminal peptide containing the GST protein tag and thrombin 
cleavage site will add approximately 26 KD to the fusion GST-mcBMP4 protein. Thus 
the predicted total MW of the recombinant mcBMP4 protein is approximately 40 KD. 
39 
1 2 3 4 5 6 7 8 9 10 11 
370 bp 
Figure 8. Gel analysis of colony PCR results obtained from individual E. coli 
clones potentially carrying the mcBMP4 insert. One positive clone (lane 11) was 
obtained. The pGEX-KG expression vector was used to clone mcBMP4 for use in 
mcBMP4 expression in E. coli cells. Colonies were boiled for 10 min and 10 ul 
cell lysate were used for colony PCR. Lane 1= 100 bp DNA ladder; Lane2-11 = 
PCR products of selected individual E. coli clones. 
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Figure 9. Partial DNA sequencing chromatogram of pGEX-KG-mcBMP4 construct. 
Red underline: mcBMP4 sequence; Yellow highlight: Bam HI linker site. Arrow 
indicates the ligation site of the mcBMP4 insert within the pGEX-KG vector 
sequence. 
40 
MW 
(KD) 
200 
116.2 
97.4 
66.2 6 S K D 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ • ^ _ 40 KD 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ M ^ 29 KD 
21.5 
14.4 
Figure 10. SDS-PAGE analysis ofE.coli clones in screening for GST-mcBMP4 
fusion protein expression. Cells were grown in 2x YTA medium to reach an ODeoo 
of 0.6-0.8, and induced using ImM IPTG for two hours. Crude cell lysate was 
analyzed using 4-12% Bis-Tris NuPAGE gel in lx MOPs buffer, running at 200 V 
for 50 min. The gel was stained overnight using Coomassie blue right after the 
run. Lane 1=MW standards; Lane 2-6= cell lysate from selected individual clones. 
Lane 7= cell lysate from pGEX-KG transfected control cells, confirming control 
GST protein expression. 
SDS-PAGE analysis of the five selected clones (lane 2-6) indicated that all five clones 
contained the 40 KD fusion protein bands (Figure 10). Compare to other clones, clone 
A4 (lane 4) demonstrated the highest level of protein expression. The control plasmid 
(expression vector pGEX-KG without mcBMP4 insert) in the last lane produced a strong 
GST protein band with expected molecular weight of 29 KD (26 KD GST protein plus 
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3KD thrombin cleavage site). Besides the expected 40 KD fusion protein bands, a band 
with approximately 66 KD was also observed for all the clones other than control. It is 
possible that the 66KD band suggests a large conformation change upon dimerization of 
mcBMP4 to form a tight insoluble or toxic aggregate. Alternatively, it is also possible 
that some protein interactions present. The fact that more 66KD forms present in most of 
these clones than the expected 40 KD monomeric fusion protein may suggest that 
dimerization/aggregation or protein- protein association confers much greater protein 
stability than is found when the protein is monomeric. 
Fusion protein expression optimization. Optimization of the GST-mcBMP4 
fusion protein production was investigated by varying IPTG concentration, growth and 
induction temperature, and induction time. After optimization, a concentration of ImM 
IPTG, an induction temperature of 37°C, and induction time of 2 hours were used for 
subsequent inductions in 2x YTA medium. 
Small scale protein purification. Small scale (100 ml) protein expression was 
conducted under the optimal conditions listed above. GST-mcBMP4 fusion was 
produced as a monomer with apparent MW around 40 KD. After thrombin cleavage, the 
expression tag remained but the mcBMP4 was not detectable (Figure 11). Western 
blotting further confirmed the expression of GST fusion protein using anti-GST 
polyclonal antibody (Figure 12). In an effort to improve the protein yield, large scale (2 
liter) protein expression was also conducted using Bugbuster lysis reagent supplemented 
with PMSF. No significant improvement of the protein yield was observed (data not 
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Figure 11. Coomassie-stained 4-12% Bis-Tris NuPAGE gel showing GST-mcBMP4 
fusion protein expression in E.coli (2 hour induction at 37°C). Crude cell lysate was 
purified using glutathione separose 4B affinity column and eluted with 10 mM 
reduced glutathione. Gel was run at 200 V for 30 min in lx MES buffer. Lane 1= 
crude cell lysate; Lane 2= flow through; Lane 3= pooled wash fraction; Lane 
4=eluted fraction; Lane 5= eluted protein with GST tag removed after thrombin 
treatment. Lane 6= MW STD. 
40KD—H 
«-26KD 
Figure 12. Detection of GST-mcBMP4 fusion protein expression in E. coli 
using 1:1000 dilution of the anti-GST polyclonal antibody by western blot. Lane 
1= crude cell lysate; Lane 2= eluted fraction; Lane 3= eluted protein with GST 
tag removed after thrombin treatment. 
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shown). The estimated protein concentration was approximately 15 (ig/ml. Total protein 
yield is 300 mg in 2 L scale. 
Monoclonal Antibody Production 
Peptide selection. The selection of an antigenic peptide is the first and probably 
the most critical step in the production of a monoclonal antibody. For a synthetic peptide 
to be sufficiently antigenic, peptide selection should follow several principles. First, the 
length of the peptide should be 6-25 amino acids long in order to form an immunogenic 
epitope. It should be part of the mature protein, and mostly composed of hydrophilic 
residues. Regions of proteins that are mostly composed of polar residues will be more 
hydrophilic and are more likely to be exposed on the surface of the protein. It should be 
accessible and not have residues that could be sites of glycosylation. Amino acids buried 
inside an alpha helix or beta sheet will not elicit antibodies that recognize native protein. 
Furthermore, for membrane spanning proteins, the peptide should not be within the 
transmembrane domain, but should be present on the extracellular domain of the protein. 
Finally, the desired peptide region should be specific and unique, and not have high 
sequence homology with its close family members. In our project, therefore, only the 
mature region of cBMP4 with low sequence homology with other BMP proteins was 
chosen to be analyzed using Protean (DNASTAR, Madison). 
The full length cBMP4 protein sequence with its potential glycosylation sites is 
shown in Appendix 6. Multiple sequence alignment of BMP4 with its closest family 
member BMP2 indicated that only the N- terminals of the BMP4 protein diverged 
significantly in sequence homology when compared to BMP2, with the rest of the protein 
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being highly conserved (Figure 13). It was also evident that the majority of the BMP4 
residues at the N-terminals showed high sequence homology across other species, which 
may indicate that it is likely that antibodies raised against the peptides selected from this 
region may cross-react with other species. 
BMP2_Mouse QAKHK--QRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFP 
BMP2_hm QAKHK--QRKRLKSSCKRHPLYVDFSDVGWNDWIVAPPGYHAFYCHGECPFP 
BMP2_GG QAKHK--QRKRHKYSCKRHPLYVDFNDVGWNDWIVAPPGYSAFYCHGECPFP 
BMP4_Mouse SPKHHPQRSRKKNKNCRRHSLYVDFSDVGWNDWIVAPPGYQAFYCHGDCPFP 
BMP4_Hm SPKHHSQRARKKNKNCRRHSLYVDFSDVGWNDWIVAPPGYQAFYCHGDCPFP 
BMP4-GG SPKHHG--SRKNKKNCRRHALYVDFSDVGWNDWIVAPPGYQAFYCHGDCPFP 
**. ... *.** ***** ************** ******.**** 
BMP2_Mouse 
BMP2_hm 
BMP2_GG 
BMP4_Mouse 
BMP4_Hm 
BMP4-GG 
BMP2_Mouse 
BMP2_hm 
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BMP4_Mouse 
BMP4_Hm 
BMP4-GG 
LADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKWLKNYQDMWEG 
LADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKWLKNYQDMWEG 
LADHLNSTNHAIVQTLVNSVNSKIPKACCVPTELSAISMLYLDENEKWLKNYQDMWEG 
LADHLNSTNHAIVQTLVNSVNSSIPKACCVPTELSAISMLYLDEYDKWLKNYQEMWEG 
LADHLNS TNHAIVQTLVNS VNS SIPKACCVPTELSAISMLYLDE YDKWLKNYQEMWEG 
LADHLNSTNHAIVQTLVNSVNSSI PKACCVPTELSAI SMLYLDEYDKWLKNYQEMWEG 
********************** ********************* .********.***** 
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CGCR 
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Figure 13. Multiple sequence alignment of mature BMP 4 sequence with BMP2 
sequence across the species. Blue (*) identical residue. Green (:) structurally 
conserved residue. 
Four aspects of the mcBMP4 peptide sequence were analyzed using the Protean function 
of the Lasergene software: secondary structure, hydrophilicity, antigenicity and 
accessibility (Figure 14). The Lasergene software uses the original method of Chou and 
Fasman to predict helices, sheets, and turns (Chou & Fasman, 1978). The secondary 
structure of BMP4 was also predicted according to a slightly modified method of Gamier 
- Robson (Gamier, Osguthorpe, & Robson, 1993). Hydrophilicity is calculated according 
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to the algorithm of Kyte and Doolittle (Kyte & Doolittle, 1992). They evaluated the 
hydrophilic and hydrophobic tendencies of the sequence. This profile was useful for 
predicting exterior vs. interior regions of the native protein. Surface probability was 
calculated according to the formula of Emini (Emini, Hughes, Perlow, & Boger, 1985). 
Structure 
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Figure 14. BMP4 antigentic peptide selection using Protean. Four aspects of 
the peptide sequenced were analyzed: secondary structure, hydrophilicity, 
antigenicity and accessibility. 
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The antigenic index (AI) is a measure of the probability that a region is antigenic. 
It is calculated by summing several weighted measures of secondary structure (Jameson 
& Wolf, 1988). The outputs of peptide prediction were indicated in Figure 14. The N-
terminal sequence (residue 1-20) was predicted to be highly hydrophilic, accessible and 
antigenic with very little alpha helix or beta sheet structure. Together with the multiple 
sequence alignment results, one peptide sequence (SPKHHGSRXNKKNCRRH) with a 
total of 17 residues was selected for peptide synthesis. 
Screening assay optimization. The dilution of the primary and secondary 
antibody was optimized using ELISA for use in a screening assay. The dilution of 
primary antibody was started as 1:20, and then a series of two fold dilution was made. 
The dilution of secondary antibody was started at 1:500. In general, the mice immune 
response to cBMP4-KLH conjugates was very weak and no reaction was detectable when 
the immune serum's dilution was higher than 1: 40. The absorbance (405 nm) values of 
the immune serum (red bar) were considerably higher than those of the pre-immune 
serum (yellow bar) when assayed using a 1: 500 dilution of the secondary antibody 
(Figure 15). Primary antiserum dilution of 1: 20 and secondary antibody dilution of 1: 
500 were chosen to further analyze the immunogenicity of BMP4 peptide. 
The amount of peptide (500 ng to 7.8 ng) to coat the ELISA plates was also 
optimized and evaluated using three pooled immune serum dilutions (Figure 16). The 
higher the immune serum dilution, the lower the absorbance value was expected. 
However, the higher the amount of antigen coating the plate, the lower the absorbance 
intensity was found for each dilution. It seemed that the peptides were present in the 
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Figure 15. ELISA analysis using different secondary antibody dilutions. Absorbance 
(405nm) values of anti-cBMP4 immune serum at different secondary antibody dilutions. 
ELISA plates were coated with 1 |ig synthetic cBMP4 peptide and incubated with serial 
dilutions of pooled mice immune serum. A serial dilution of the primary Ab was tested 
at two different HRP conjugated secondary antibody concentrations. 
• 1/20 dilution 
• 1/40 dilution 
1/80 dilution 
500 600 200 300 400 
Peptide/well (ng) 
Figure 16. ELISA analysis using different amounts of cBMP4 peptide antigen. 
Absorbance (405nm) values of samples containing different amounts of synthetic cBMP4 
peptide antigen (7.8-500 ng) reacted with three dilutions of pooled immune serum in 
ELISA using 1:500 dilution of HRP conjugated rabbit anti-mouse secondary antibody. 
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appropriate conformation without overlapping on each other only when small amount of 
peptide was used to coat the plates. The highest absorbance detected using 7.8 ng peptide 
was used to coat the plates. 
Immune serum specificity was evaluated by competitive ELISA. Three immune 
serum dilutions were made and pre-absorbed with 500ng cBMP4 antigenic peptide for an 
hour. The mice immune response to cMBP4 peptide was specific since immune serum 
had higher absorbance value than that of pre- absorbed immune serum at all three 
different dilutions, especially at the highest immune serum dilution (1:80). As we 
expected, the antibody produced is specific since the higher the antibody dilution, the 
lower the amount of antibody would present after it was pre-absorbed with the antigen, 
and therefore, the lower the absorbance (Figure 17). 
Monoclonal antibody production. The mouse immune response to the antigenic 
peptide was weak, and no hybridomas secreting specific antibody were detected (data not 
shown). Monoclonal antibody production was discontinued. 
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Figure 17. Competitive ELISA analysis. Absorbance (405nm) values of 
samples containing different amounts of synthetic cBMP4 peptide antigen (7.8-
500 ng) reacted with three dilutions of pooled immune serum or pre-absorbed 
immune serum in competitive ELISA using 1:500 dilution of HRP conjugated 
rabbit anti-mouse secondary antibody. The pre-absorbed immune serum was 
prepared by incubation with 500ng cBMP peptide for one hour before adding to 
the ELISA plates. 
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Discussion 
Cardiac septation defects and valve malformation are the most common 
congenital birth defects. Recently, congenital heart malformation studies using mouse 
and chick models have revealed critical yet still poorly understood roles of BMP4 in 
cardiogenesis. BMP4, for example, appears to be involved both in EMT formation and 
apoptosis in both endocardial cushions and ventricular myocardium during embryo 
cardiogenesis (Zhao & Rivkees, 2000). BMP4 has also been identified as a signaling cue 
from myocardium directly mediating atrioventricular septation (Jiao et al., 2003). Defects 
in this process cause one of the most common human congenital heart abnormalities, 
atrioventricular canal defect, but the role of BMP4 in septum formation remains unclear. 
In order to further explore potential roles of BMP4 during embryonic heart development, 
time course studies mapping BMP4 mRNA expression patterns have recently been done 
using in situ hybridization (Somi et al., 2004). These expression studies, however, are 
still incomplete with respect to the stages of development examined and the specific 
regions of the heart investigated. Moreover, the BMP4 mRNA expression patterns may 
not necessarily represent BMP 4 protein expression and final deposition patterns. BMP4 
is, after all, a secreted protein, and identifying where its origin will not necessarily reveal 
its field of deposition within the tissue nor its domain of action. Unfortunately, so far 
only one published paper has focused on immunolocalization of BMP4 protein to 
examine its expression domain in the development of embryonic endocardial cushions. It 
is absolutely critical, therefore, to further examine BMP4 protein expression patterns to 
facilitate our understanding of its function in embryonic heart development. 
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We selected the chick as research model to carry out a time course study on 
BMP4 protein expression, although the mouse is often preferred (since it is more closely 
related to humans than are avians). There are, however, many inherent and practical 
drawbacks to the use of the mouse as a model organism as opposed to the chick, 
including much higher animal care/housing expenses, more restrictive regulations 
regarding the use of mice in animal research, inaccessibility of the embryos during 
development (and thus an inability to assess the developmental stage of the embryo prior 
to harvest and an inability to carry out any surgical manipulation, viral transfection or 
microinjection), the fact that adult animals need to be sacrificed to obtain embryos, the 
longer gestation time relative to the chick. Like the mouse, the chick too possesses a four 
chambered heart and a circulatory system extremely similar to that of the human, with a 
high degree of conservation in structural and regulatory genes. Finally, chick embryos 
have been extensively studied by embryologists for 100 years, and many developmental 
stages have a number of well-defined anatomical markers that aid in staging of the 
embryos. 
To localize BMP4 protein expression domains during early embryonic 
cardiogenesis, a specific, high affinity antibody would prove an invaluable tool, and the 
homogeneity of antibody isotype, antigenic (epitope) specificity, consistent titer etc 
exhibited by a monoclonal antibody would be particularly beneficial. Despite the clear 
utility of such a reagent, however, anti-chick BMP4 antibody is still not commercially 
available, and the cross-reactivity between anti-human BMP4 mAbs (which are available) 
against chick BMP4 remains untested by any of the antibody manufactory companies 
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contacted so far. The short-term goal of this project then was the production of BMP4 
protein for use as an immunogen in the generation of a BMP4 mAb. Producing a mAb 
using a synthetic BMP4 peptide was also sought simultaneously since this approach 
might succeed in generating a mAb without waiting for large amounts of BMP4 to be 
purified. 
There are three commonly used approaches for monoclonal antibody production 
based on the different nature of the immunogen: (i) production using natural proteins, (ii) 
production using recombinant proteins, and (iii) production using one or more synthetic 
peptides that correspond to specific regions of the native immunogen. Natural proteins 
are perhaps the ideal immunogens, providing sequence-specific and surface structural 
epitopes. Natural proteins such as BMP4, however, are often expressed in small amounts. 
Early attempts to extract BMP protein from bovine bone powder indicated that only 40 
jag of protein could be obtained from 40 kg quantities of bovine bone powder (Wozney et 
al., 1988). Obtaining adequate amounts of BMP4 from chick embryos as immunogen, 
therefore, is most likely impractical, since it will probably require excessive amounts of 
embryos as starting material. 
Recombinant fusion proteins produced in mammalian cells or bacteria are also 
used successfully to produce antibodies recognizing specific, three-dimensional 
determinants. We also adoped this approach, choosing to express a mature cBMP4 
fusion protein in both mammalian cells and bacteria cells. Ideally, such an approach 
would produce enough protein both for use as an immunogen in the production of a mAb 
and for hybridoma screening purposes. 
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As a third approach, synthetic peptides conjugated to carrier proteins can 
sometimes be used to generate antibodies. Although the cost of peptide synthesis is high 
and the antibody ultimately produced may not recognize the native protein, the 
advantages of the approach are significant. First, the investigator can, using various 
bioinformatics tools, design a peptide from a region of the protein that is unique to that 
protein (especially useful when the protein is one member of a large class of structurally 
related family members). Secondly, the synthetic peptide can be made easily and quickly, 
allowing immunization to be started right away. Third, the protein domain recognized by 
the antibody is unambiguously defined, allowing its use in structural antigen mapping 
studies. Finally, the defined nature of the immunogen allows the immunogenic peptide to 
be used later as a blocking peptide, a very valuable reagent when trying to prove 
specificity of binding. Considering the time frame of this project and the intrinsic 
difficulty of recombinant protein production, the use of a synthetic peptide was deemed a 
viable approach for antibody production, and worth an effort despite its disadvantages. 
Recombinant Protein Expression in Mammalian Cells 
Mammalian cells are commonly used for production of recombinant proteins, 
especially those of vertebrate origin. In contrast to lower eukaryotes or prokaryotes, 
mammalian cells possess the appropriate protein processing machinery and often provide 
active recombinant proteins that possess important post-translational modifications 
(glycosylation, phosphorylation, proteolytic modification, etc.) required for in vivo 
function. Stable expression technologies, based on chromosome-integrated plasmid 
sequences and amplifiable expression cassettes such as the dihydrofolate reductase or 
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glutamine synthetase system, have been shown to provide high levels of recombinant 
protein expression up to the grams-to-kilograms scale. There are, however, several 
disadvantages associated with stable expression systems. Development of stable cell 
lines requires a considerable investment in time, expensive additional reagents (especially 
selection antibiotics), human resources and lab equipment. In contrast, transient 
expression provides an economic alternative approach for protein production in the 
milligram-to-gram scale, which is more suitable for small-scale research purposes. 
In order to get proper folding protein with bioactivity, the best approach for 
recombinant protein production is to produce native cBMP4. Due to intrinsic difficulties 
in cloning the entire coding region of BMP4, however, the mature region of BMP4 was 
selected instead. Masuhara et al. (1995) found that homodimeric protein can be used to 
produce monoclonal antibody that can also recognize the native dimeric BMP protein. In 
this study, the mature region of chick BMP4 was cloned into the mammalian expression 
vector pcDNA4 /HisMax, and then transiently expressed in COS-7 cells. The fusion 
mcBMP4 was apparently produced as a monomeric protein with molecular weight about 
16.2 KD as shown by western blotting, suggesting that the disulfide bond was not linked 
through the seventh cystine residue intermolecularly to form the BMP4 homodimer (as 
opposed to native BMP4) although mammalian cells should provide all the machinery 
necessary for protein dimerization. One possible explanation of this phenomenon is that 
either the absence of both the signal peptide and the prodomain of the BMP4 or the 
addition of the N-terminal fusion tag may greatly impact the BMP4 protein processing 
and trafficking in the mammalian cells, with the result that the protein dimmer is not 
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formed effectively. It is also possible that without the prodomain, the recombinant 
BMP4 protein is not folded in the correct conformation, in turn causing misalignment of 
the critical cystein residues and thereby preventing formation of the homodimer. The 
fusion protein was folded in such a way that the binding of the purification tag (especially 
the 6-histidine residue) to the nickel-chelating column was prevented. The fact that 
mcBMP4 was only present in the crude cell lysates and the nickel affinity column flow-
through fraction during protein purification (instead of column elution fractions as 
expected) tends to support this hypothesis. 
Besides the problem associated with protein misfolding, the level of fusion 
protein expression was low. No strong bands with expected molecular weight of 16.2KD 
were detected in the SDS-PAGE gels following staining by Coomassie Blue. To further 
explore the reasons underlying this low level of expression, three key features critical to 
optimal small scale transient transfection and recombinant protein expression in 
mammalian cells were evaluated: (i) the nature of the host cells, (ii) the nature of the 
expression vector, and (iii) the nature of the transfection system. 
i) Host Cells. Three cell types have been the most popular for transient 
recombinant protein expression: human embryonic kidney (HEK)-293 cells, COS cells 
and baby hamster kidney (BHK) cells. Interestingly, although CHO cells (the most 
widely used host for stable recombinant protein expression) are more frequently used for 
recombinant BMP protein expression, they have failed so far to give satisfying 
expression levels when transfected transiently (Wurm & Bernard, 1999). Like CHO, 
COS cells are routinely grown as adherent cultures, can be grown to fairly high density, 
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can be adapted to a variety of growth media etc. Human recombinant BMP4 was first 
transiently expressed in COS-1 cells to determine the in vivo activities of the BMP 
polypeptides (Wozney et al., 1988). Fifteen years later, another BMP family member 
structurally similar to BMP4 (human recombinant BMP7) was successfully produced as a 
mature, disulfide-linked, biologically active homodimer in COS-7 cells (Lee et al., 2003). 
Those studies supported the idea that at least some clones of COS cells could serve as a 
functional host for recombinant BMP4 expression, and served as a major justification for 
our selection of COS-7 cells in this study. The COS-7 cell is an African green monkey 
kidney fibroblast-like cell line suitable (like most other COS cell lines) for transfection 
by vectors requiring expression of SV40 T antigen, and will allow episomal amplification 
of plasmids containing a SV40 origin of replication. The use of such plasmids as 
expression vectors, therefore, would be expected to increase recombinant protein 
expression levels by permitting more plasmid copies to persist in the transfected cells 
throughout the production phase (Van craenenbroeck, Vanhoenacker, & Haegeman, 
2000). 
ii) Expression vector. There are many expression vectors available commercially. 
One important issue for high level recombinant protein expression is to use vectors with 
promoters that are highly active in the host cell line chosen. One example of such a 
strong, constitutively active promoter active in COS cells is that adapted from the human 
cytomegalovirus (CMV). Plasmids that carry an SV40 origin of replication will also 
enable vector replication in COS cells (which constitutively produce the SV40 T antigen 
required for SV40 genome replication), thereby increasing the plasmid copy number and 
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thus the transcriptional capacity for recombinant protein production. Another big 
consideration in vector choice is the presence of structural modification cassettes (which 
encode protein purification motifs or tags) and the ease with which those modifications to 
the recombinant protein will facilitate downstream purification. The pcDNA4/HisMax 
vector from Invitrogen was selected because it carries a CMV promoter, possesses an 
SV40 origin of replication and produces a recombinant 6-His tagged protein, allowing 
convenient and efficient metal-chelation affinity purification. It is instructive to note, for 
example, that the pcDNA3.1/HisMyc vector (which possesses a backbone essentially 
identical to that of pcDNA4/HisMax) was able to replicate up to 10,000 copies in cells 
expressing large T antigen (Chittenden, Frey, & Levine, 1991). Besides high copy 
number, our vector also contains a QBI SP 163 translational enhancer, which increases 
expression of recombinant protein via a cap-independent translation mechanism. Other 
useful features of this vector include the presence of the Xpress epitope (which can 
facilitate protein detection in vivo) and the presence of an Enterokinase cleavage site 
(which allows removal of N- terminal tag from to create the native protein). 
iii) Transfection system. The transfection system is another important factor to 
consider about because it is related to gene transfer efficacy. There are many highly 
effective gene transfer reagents and methodologies commercially available: (a) the 
DEAE-dextran method, (b) the calcium-phosphate method, (c) electroporation, (d) 
ballistic methods, (e) transfection using recombinant viruses, and (f) lipid and liposome-
mediated transfection. DEAE-dextran was one of the first chemical reagents used for 
transfer of nucleic acids into cultured mammalian cells. DEAE-dextran is a cationic 
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polymer that associates with negatively charged nucleic acid. The positive charged 
polymer enables the DNA polymer complex to come into closer association with the 
negatively charged cell membrane, ultimately facilitating uptake into the cells by 
endocytosis. 
Calcium phosphate co-precipitation is also widely used for transfection. Mixing 
DNA with calcium chloride in PBS will allow the mixture to precipitate and disperse on 
to the cultured cells. The precipitates can then be taken up by the cells via endocytosis or 
phogocytosis. This method is widely used because the components are easily available 
and reasonable in price, but the transfection efficiency is low with low reproducibility. 
Electroporation is one of the physical methods for gene transfer. The mechanism 
for entry into the cell is based upon perturbation of the cell membrane by an electrical 
pulse, which forms pores that allow the passage of nucleic acids into the cell. Although 
high transfection efficiency can be achieved using electroporation, the technique requires 
an expensive electroporator and the cell mortality is high. In addition, fine-tuning and 
optimization for duration and strength of the pulse for each type of cell are critical to 
achieve a fine balance between conditions that allow efficient delivery and conditions 
that kill cells. 
Liposome mediated delivery has been widely used to deliver DNA into cells. 
Unlike the DEAE-dextran or calcium phoshate chemical methods, liposome mediated 
nucleic acid delivery can be used for in vivo transfer of DNA and RNA to animals and 
humans. Invitrogen's Lipofectamine 2000 is one of many cationic lipid-based 
transfection reagents presently on the market. Lipofectamine is formulated to give high 
59 
transfection efficiency with little toxicity to cells. Invitrogen claims that this reagent 
gives the highest protein expression levels in the widest variety of adherent and 
suspension mammalian cell lines compared to similar products. Researchers found that 
greater than 90% efficiency can be achieved consistently for use lipofectamine to 
transfect a range of cell lines such as HEK-293, CHO and COS-7. Lipofectamine 2000 
was used as the transfection agent in this study and it indeed showed very high 
transfection efficiency (more than 95%). 
In this study, the design of the mammalian expression system was carefully 
weighed against the basic criteria discussed above. Since the low expression level does 
not appear to be due to the cell line, expression vector or transfection method, the 
possibility that low protein expression is largely dependent on the nature of the protein 
must be considered. In fact, a previous study also showed that the transient expression 
level of BMP proteins were found very low in COS cells. In that study, the level of 
expression was dependent on the individual BMP being expressed, but in the best case 
there was less than 1 percent of the total protein produced (Wozney et al., 1988). 
Another explanation for the observed low protein expression may be protein misfolding, 
with the misfolded protein perhaps being targeted for lysozomal degradation. 
Recombinant Protein Expression in E. Coli 
Relative to mammalian cells, expression in E. coli is simple and inexpensive. 
Because of the difficulties encountered in producing large amounts of mcBMP4 in 
mammalian cells (and associated protein purification problems discussed in the above 
section), as an alternative approach, expression of mcBMP4 in a bacterial system (E. coli, 
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BL-21 strain) was attempted to produce sufficient protein for immunization. Monomeric 
mouse mature BMP4 produced in E. coli might elicit the production of a monoclonal 
antibody that could recognize the native dimeric BMP protein. 
E. coli is a gram-negative bacterium containing two membranes: (i) an inner 
membrane separating the cytoplasm from the periplasm, and (ii) an outer membrane to 
protect the bacterium from the surrounding environment. The heterologous protein 
expressed in E. coli cells can be directed to the reducing cytoplasm or the comparatively 
oxidizing periplasm, which facilitates disulfide bond formation. Although for 
heterogeneous protein composed of several disulfide bonds, periplasm expression is an 
ideal choice, one inherent drawback of targeting protein secretion to the periplasm is that 
poor secretion of protein across the inner membrane will result in low protein yield upon 
purification. As a secondary consequence of impeded protein transport across the plasma 
membrane, accumulation of the recombinant protein in the periplasm can sometimes 
produce significant cytotoxicity. For that reason, heterologous protein is often targeted in 
cytoplasm. 
In this study, the recombinant GST-mcBMP4 protein yield was relatively low, 
possibly due to low protein solubility. Although the production of recombinant fusion 
proteins in E. coli is a well- established technology, some of these factors that may limit 
production and purification of soluble fusion proteins include: (i) host strains, (ii) the 
nature of the expression vector, (iii) growth conditions encountered by the recombinant 
organism, and (iv) the conditions used to induce recombinant protein synthesis. 
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i) Host strain. A wide variety of E. coli host strains can be used for cloning and 
expressing recombinant protein. Strains deficient in known cytoplasmic protease gene 
products, such as Lon, OmpT, DegP or HtpR may aid in the expression of fusion proteins 
by minimizing the effects of proteolytic degradation by the host. An example of such a 
host strain is E. coli BL-21, a strain defective in OmpT and Lon protease production. BL-
21 is a well-established strain proved to be able to express the fusion protein in a soluble, 
intact form. In our project, BL-21 strain was used for cBMP4 protein expression. 
ii) Expression vector. A glutathione S-transferase (GST) based gene fusion and 
expression vector, pGEX-KG, was generously provided by Dr. Julio Soto (whose 
laboratory routinely uses this vector for recombinant protein expression). This vector is a 
versatile system for the expression, purification, and detection of fusion proteins 
produced in E. coli, and is based on inducible, high-level expression of a gene (or gene 
fragment) fused in frame with the Schistosoma japonicum GST coding region. 
Expression in E. coli yields fusion proteins with the GST moiety at the amino terminus 
and the protein of interest at the carboxyl terminus. Expression is under the control of the 
tac promoter, which is induced by the lactose analog IPTG. All pGEX vectors are also 
engineered with an internal taclq gene, the product of which is a repressor protein that 
binds to the operator region of the tac promoter to prevent expression until induction by 
IPTG, thus maintaining tight control over expression of the insert. In addition to offering 
chemically inducible, high-level expression, the vectors allow mild elution conditions for 
release of fusion proteins from the affinity medium. The protein produced would 
accumulate within the cell's cytoplasm. 
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iii) Growth conditions encountered by the recombinant organism. Growth 
parameters are critical in regulating the yield of non-degraded fusion protein. Important 
variables include growth temperature, duration of the induction period, degree of culture 
aeration and cell density, the optimization of which often requires striking a balance 
between yield and quality of the desired recombinant protein. Low temperature growth 
conditions, for example, can sometimes minimize protein misfolding. This, in turn, will 
increase protein quality (where properly folded protein is considered to be of higher 
quality). Since properly folded protein tends to be more soluble, such growth conditions 
also tend to minimize protein aggregation, increasing potential recovery and yield. Cells 
grow much slower, however, at reduced temperatures. The decreased cell density tends 
to reduce the yield. In this experiment, due to time, expense and cell culture system 
limitations, growth temperatures below 30°C, changes in aeration, nutrient 
supplementation during induction, etc. were not tested. We found cultured cells at 30°C 
resulted in no significant improvement of protein quality or yield. 
iv) The conditions used to induce recombinant protein synthesis. Many 
heterogeneous proteins fail to fold into their native state when overexpressed in E.coli. 
Instead, they are either degraded by the cellular proteolytic machinery or accumulated in 
insoluble form, typically as inclusion bodies. Inclusion bodies are large in size, resist 
proteolysis and hence can be easy to purify from other cellular components. Purified, 
insoluble inclusion bodies can be solubilized under strong denaturing conditions such as 
8 M urea or 6 M gauanidium chloride, and removal of denaturants sometimes allows 
refolding of the denatured protein. Unfortunately, the best conditions for refolding are 
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empirically determined from a set of general guidelines for refolding (Buchner & 
Rudolph, 1991J and can be painstaking to perform. Optimizing inducing conditions 
could also potentially increase protein yield through increasing protein solubility. The 
inducing conditions include varying the concentration of IPTG and duration of the 
induction time. We observed that varying IPTG induction conditions (0.1 mM to 1 mM 
IPTG) or duration of the induction time made no significant difference in protein 
solubility or yield. 
Monoclonal Antibody Production 
We designed and obtained synthetic peptides for use in immunizing mice for 
antibody production. This approach, however, did not prove successful. The mouse 
immune response to the peptides was very low, producing antisera with only weak 
immunoreactivity (maximum immune serum titer reached a value of only 80). Due to the 
low immune response, the hybridomas we obtained following fusion were incapable of 
producing antibodies of any significant titer against BMP4. Factors that could contribute 
to low mouse immune responses included: i) choice of host, ii) peptide selection, iii) 
selecting the protein carrier and iv) coupling strategy. 
i) Choice of host. The animal chosen for immunization should be genetically very 
different from the animal chosen as the source of the immunogen. In order to achieve a 
maximum immune response, it is important to avoid self-recognition of the immunogen 
by the host animal. Although selection of mouse as the host to produce anti-chick BMP4 
antibody seems to be a good choice, there is a large homogeneity of BMP4 across the 
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species. Thus the mouse may have some self-tolerance for this protein, which may 
contribute to the low immune response. 
ii) Peptide selection. There are several elements that may impact the antigenicity 
of the peptide. First, the selected region should be unique. The region of the peptide 
selected should be from the mature region, should not possess a site of glycosylation and 
should represent a unique sequence that would help ensure specificity to the target 
protein. Second, the peptide should be hydrophilic, flexible and accessible. Since most 
naturally occurring proteins in aqueous solutions have their hydrophilic residues on the 
surface and their hydrophobic residues buried in the interior, the selected peptide should 
be hydrophilic, surface oriented and flexible in order to produce antibody recognize the 
native protein. The highest point of average hydrophilic for a series of contiguous 
residues is usually at or near an antigenic determinant (Hopp & Woods, 1981). Because 
the C-termini or N -termini of proteins are often exposed and have a high degree of 
flexibility, they are usually a good choice for generating anti-peptide antibodies directed 
against the intact protein. In our case, the peptide we selected is located in the N-
terminal with high accessibility, hydrophilicity and flexibility. Third, the structure of the 
peptide should be accessible. If the 3D structure of the protein is known, this can greatly 
assist in choosing exposed epitopes. Surface regions or regions of high accessibility 
often border helical or extended secondary structure regions. In addition, sequence 
regions with beta-turns or amphipthic helix character have been found to be antigenic 
(Parker & Hodges, 1991). Fourth, the length of the peptide should be appropriate. There 
are two different thoughts on the topic of peptide length. One suggests that long peptides 
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(20-40 amino acids in length) are optimal because it increases the number of possible 
epitopes. The other suggests that smaller peptides are sufficient, and their use ensures 
that the site-specific character of anti-peptide antibodies is retained. Any peptide selected 
must be chemically synthesizable and should be soluble in aqueous buffer for conjugation 
to carrier proteins. Peptides longer than 20 residues in length are often more difficult to 
synthesize with high purity because there is greater potential for side reactions, and they 
are likely to contain deletion sequences. On the other hand, short peptides (<10 amino 
acids) may generate antibodies that cannot recognize the native protein. The typical 
length for generating anti-peptide antibodies is in the range of 10-20 residues. Peptide 
sequences of this length minimize synthesis problems, are reasonably soluble in aqueous 
solution and may have some degree of secondary structure. The peptide length we 
selected is within this range. 
iii) Selecting the protein carrier. Conjugation to a carrier protein is important 
because peptides are small molecules and do not tend to be immunogenic. The carrier 
protein contains many epitopes that stimulate T helper cells, which helps induce the B 
cell response. Many different carrier proteins can be used for coupling to synthetic 
peptides. The most commonly selected carriers are keyhole limpet hemacyanin (KLH) 
and bovine serum albumin (BSA). The higher immunogenicity of KLH often makes it 
the preferred choice. Another advantage of choosing KLH over BSA is that BSA is used 
as a blocking agent in many experimental assays. KLH was used for conjugation in our 
project. 
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iv) Coupling strategy. The coupling site and technique utilized also play 
important roles in determining the reactivity of the antibodies. Generally, peptides can be 
coupled to other proteins by utilizing: a) A free NH2 or COOH (recommended for 
peptide when Cysteine cannot be added to the peptides); b) A free Cysteine group 
(available as part of the sequence or added at the N or C-terminus). The coupling method 
utilized in our project was Glutaraldehyde method, which is empirically selected based 
on the recommendation of the peptide synthesis scientist at ADI International. 
Glutaraldehyde is a bifunctional coupling reagent that links two compounds through their 
amino groups. Glutaraldehyde provides a highly flexible spacer between the peptide and 
carrier protein for favorable presentation to the immune system. Unfortunately, 
glutaraldehyde is a very reactive compound and will react with Cysteine, Tyrosine and 
Histidine to a limited extent. The result can be a poorly defined conjugate. The 
glutaraldehyde method is particularly useful when a peptide contains only a single free 
amino group at its amino terminus. If the peptide contains more than one free amino 
group, large multimeric complexes can be formed, which are not well defined, but are 
highly immunogenic. 
Although the selected cBMP4 peptide meets all these criteria, immunogenic 
capacity of a peptide not only depends on intrinsic chemical properties of the peptide but 
also on extrinsic factors such as the host immunoglobulin repertoire, self-tolerance and 
various cellular and regulatory mechanisms definable only in the context of the host (Van 
Regenmortel, 2001). A strong humoral immune response directed against the peptide is 
thought to require the stimulation of two cell types. Specific pre-B lymphocytes must be 
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stimulated by the binding of the peptides to their immunoglobulin receptors. These cells 
mature into the antibody secreting lymphocytes. A strong response also requires the 
stimulation of helper T lymphocytes by the interaction of the carrier portion of the 
peptide-carrier complex with the appropriate T lymphocyte cell surface receptor. Thus, 
an effective immune response will largely depend on the interaction of peptide carrier 
with both B cells and T cells. The immunogenicity of a peptide is not completely 
understood, but low mice immune response may be influenced by several uncontrollable 
factors in the host such as accessibility to binding by the B cell surface receptors, ability 
of the carrier to stimulate helper T cell production, stability of the immunogen with 
respect to macrophage degradation and presentation to the immunes system, size of the 
reacting B and T cell populations, etc. (Shinnick, Sutcliffe, Green, & Lerner, 1983). 
Future Directions 
This study has shown that recombinant mature chick BMP4 (mcBMP4) can be 
expressed in both COS-7 cells and E. coli cells, but at levels too low to be of any 
practical use for the production of immunogenic protein and monoclonal antibody 
generation. It was unsuccessful to express mature BMP4 protein a monomer. Producing 
correctly folded mcBMP4 protein may require cloning and expressing of a full length 
BMP4 pre-protein. In that case, firstly, it would be necessary to redesign both the PCR 
primers (to include restriction enzyme sites for oriented cloning) and the expression 
vector (to allow production of a fusion protein carrying a C-terminal tag immediately 
downstream of an enterokinase site). The vector modifications would hopefully allow 
proper folding of the BMP4 precursor and subsequent proteolytic processing of the pre-
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protein into a mature disulfide-linked BMP4 dimer. Ideally, such folding and proteolytic 
processing would occur normally for the recombinant BMP4 fusion protein despite the 
presence of the C-terminal purification tag (His domain, GST domain, etc.). If it was 
later decided to remove the tag, the presence of the enterokinase cleavage site would 
facilitate this effort. The stop codon at the end of the chick BMP4 DNA coding 
sequence, for example, would need to be altered (using site directed mutagenesis) in 
order to allow expression of cBMP4 with fusion tag at the end. 
Secondly, given the known processing requirements and their apparent necessity 
for protein stability, expression in eukaryotic cells will be required. Switching the 
position of the tag to the C-terminal end would also facilitate inclusion of the secretion 
signal at the N-terminus. In order to improve the protein yield, generation of a stable 
expression cell line might be a reasonable alternative to transient expression, especially 
considering the low expression level observed with the current construct. Finally, the cell 
line selected for stable expression could be adapted for suspension culture since the 
culture volume can be easily expanded prior to use in protein purification. This would 
facilitate starting from a greater initial number of cells and aid in the isolation of more 
BMP4 protein. 
The use of synthetic peptides as immunogens for monoclonal antibody production 
should be pursued using a combination of two or more peptides together to immunize 
mice, stimulating a stronger immune response than a single peptide. At least one peptide 
should be selected from the unique region of the cBMP4 protein, and the others could be 
selected from evolutionary conserved regions of the cBMP4. Any hybridomas resulting 
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from this immunization strategy should be screened against the unique region antigenic 
peptide to minimize the possibility of selecting mAbs that recognize the conserved 
region. Efforts to design two or three such immunogenic peptides are currently 
underway. 
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Appendix 1. IACUC approval of using mice for monoclonal antibody production. 
San Jose State University 
Institutional Animal Care and Use Committee 
LETTER OF OFFICIAL PROTOCOL REVIEW 
Date; November 1 7, 2006 
Dear Dr. White 
The animal care and use portion of your research proposal indicated below was reviewed 
by the Institutional Animal Care and Use Committee (IACUC). The status of your 
proposal is as follows: 
Principal Investigator(s): Steven White, Sherry Li 
Protocol #: 867 
Title: Production of Monoclonal Antibody to Detect Bone Morphogcnetic 
Protein (BMP4) Expression Domain During Chick Hear t 
Development. 
The application was approved without modification by the IACUC 
Approval date: June 1,2005 * Expiration Date: May 3 1 . 2007 
The IACUC must be informed in writing of any proposed changes to the approved 
protocol outline and approval must be granted in writing by the IACUC before any 
change is instituted. If you wish to continue the approved outline beyond the expiration 
date listed, it is required that you submit a request for protocol approval extension for 
IACUC consideration in April 2007. 
The protocol number (#867) may only be used by the principal investigator and 
participants included on the approved application form. I'he protocol number will be 
required to order animals (maximum of 9 mice and 24 fertile chicken eggs) and be 
included on grant or contract proposals to lhn<\ the project. Please notify the UAC office 
for placing animal orders or to request the transfer of live animals to or from this 
approved protocol. 
If you iiave any questions, feel free to contact, me at 408-924-4929. 
I'liis protocol lias lH'i'ii approved as II lli-ullli 
Kisk C'ali-uiiryOiic l i \ e l project (I(C'-I). 
I'lcusc ri'li'r lo the ;illiiclu(l risk c:i(C(ior\ 
ilosci'iption psi^e for relet mil pci MIIIIICI 
s;ifcl> iiiloriMHlioii p n (liiniiifj lo this Muily 
^ytA/V-"-*1 £ 
Larry Young, RvjT, LAJg 
IACUC Coordinator 
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Appendix 2. Verification of mcBMP4 insert identify and orientation in pcDNA4/HisMax 
mammalian expression vector by BLAST search. 
Gallus gallus bone morphogenetic protein 4 (BMP4), mRNA 
Score = 654 bits (354), Expect = 0.0 
Identities = 354/354 (100%), Gaps = 0/354 (0%) 
Strand=Plus/Plus 
Query 287 AGCCCCAAGCACCACGGTTCCCGCAAGAACaaaaaaaaCTGCCGCCGCCACGCTCTCTAT 346 
I I I I I I I I I I I I I I M I I I I I M M I I I I I I I I I I I I I I I I I I I M I M I I I I I M I M I 
Sbjct 874 AGCCCCAAGCACCACGGTTCCCGCAAGAACAAAAAAAACTGCCGCCGCCACGCTCTCTAT 933 
Query 34 7 GTGGATTTCAGCGACGTGGGTTGGAACGATTGGATCGTGGcccccccGGGCTACCAGGCG 4 06 
I l i l l l l l l l l l l l l l l l l l l l i l l l l l l l l i l l l i l l l l l l l l l l i l l l M M M I I I I 
Sbjct 934 GTGGATTTCAGCGACGTGGGTTGGAACGATTGGATCGTGGCCCCCCCGGGCTACCAGGCG 993 
Query 4 07 TTTTACTGCCACGGGGACTGCCCCTTCCCTCTGGCCGACCACCTCAACTCCACCAACCAC 4 66 
l i l l l l l l l l M I I M I i l l l l l l l l l M M I I I I I I I i l M l l l l l l l l l i l i l l l l l l 
Sbjct 994 TTTTACTGCCACGGGGACTGCCCCTTCCCTCTGGCCGACCACCTCAACTCCACCAACCAC 1053 
Query 467 GCCATCGTGCAGACGTTGGTCAACTCCGTCAACTCCAGCATCCCCAAGGCCTGCTGCGTG 526 
M I I I I I I I I I M I I I M I I I I I I M M I M I I I I I I I I I I I I I M I I I I I I I M I i l M 
Sbjct 1054 GCCATCGTGCAGACGTTGGTCAACTCCGTCAACTCCAGCATCCCCAAGGCCTGCTGCGTG 1113 
Query 527 CCCACGGAGCTGAGCGCCATCTCCATGCTCTACCTGGATGAGTATGACAAGGTGGTGCTG 586 
I I M I I I I M I I I M I I I I I I I I I I M I I i l M l l l i l M M I i l l l l l l l l l l l i l l l l 
Sbjct 1114 CCCACGGAGCTGAGCGCCATCTCCATGCTCTACCTGGATGAGTATGACAAGGTGGTGCTG 1173 
Query 587 AAAAACTACCAGGAGATGGTGGTGGAGGGGTGCGGGTGCCGCTGACCCCTTCCC 640 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I M I I M I I i l l l l l l l l i l i l l l 
Sbjct 1174 AAAAACTACCAGGAGATGGTGGTGGAGGGGTGCGGGTGCCGCTGACCCCTTCCC 1227 
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Appendix 3. Verification of mcBMP4 insert identify and orientation in pcDNA4/HisMax 
mammalian expression vector by DNA sequencing. 
SngJtC2-T7 
M»yl9.20M.4:»l« SgMlG:lS7A:l»TH94C2» 
15 55 T5 ^ 5 S *5 W 15 ** i^ > JJ5 £55 
tcMeMMa<mc««*M«m*c«kcMt«MmTi!iMut«ccocMecftccitcw*?cec' r««»ec«oM:»crctcrAi«T»*trna(«c»AO>i»M7t8w 
*e«i*ia<MHC«NKKWoeec»<wcMteaw«e<mit«j«««a«««^ 
-JB5 SB SJ wo as us m Vfe "Tiit" 
wc^tMMC*teeocMi««eeMef*CMtee«ieMMerM«e<camteAWiw^ 
w*«mceKfMeGce»GeccM)MMeca«i**««t*MriHmM«wr^^ 
"SB— *w m m m sis sis sis m in 
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Appendix 4. Verification of mcBMP4 insert identify and orientation in PGEX-KG E. coli 
expression vector by BLAST search. 
Gallus gallus bone morphogenetic protein 4 (BMP4), mRNA 
Score = 647 bits (347), Expect-0.0 
Identities = 347/347 (100%), Gaps = 0/347 (0%) 
Strand=Plus/Plus 
Q u e r y 54 CAGCCCCAAGCACCACGGTTCCCGCAAGAACaaaaaactaCTGCCGCCGCCACGCTCTCTA 113 
I M I I I M M I I I M I I I M I I I I M I I I I I M I M M I I I I I I I I I I I M M I I I I I I ! 
Sbjct 873 CAGCCCCAAGCACCACGGTTCCCGCAAGAACAAAAAAAACTGCCGCCGCCACGCTCTCTA 932 
Query 114 TGTGGATTTCAGCGACGTGGGTTGGAACGATTGGATCGTGGCCCCCCCGGGCTACCAGGC 173 
I ] F 1 1 1 1 1 1 1 i I) I [ 11 [! I i I f I f I! 11 111 I E 1 1 1 1 1 1 1 E 1 1 1 J I F 1 1 1 1 1 1 I 11! 11 
Sbjct 933 TGTGGATTTCAGCGACGTGGGTTGGAACGATTGGATCGTGGCCCCCCCGGGCTACCAGGC 992 
Query 174 GTTTTACTGCCACGGGGACTGCCCCTTCCCTCTGGCCGACCACCTCAACTCCACCAACCA 233 
M I I I I I I I I I M I I I I I I M I I I I i l l l l l l l l l l l l l M I I I I M I I M M M I I I I I 
Sbjct 993 GTTTTACTGCCACGGGGACTGCCCCTTCCCTCTGGCCGACCACCTCAACTCCACCAACCA 1052 
Query 234 CGCCATCGTGCAGACGTTGGTCAACTCCGTCAACTCCAGCATCCCCAAGGCCTGCTGCGT 293 
I I I I I I I I I I I I I I I I I I I M I i l l l l l l l M I I I I I I I I I I I I I I M I I I M I I M I M 
Sbjct 1053 CGCCATCGTGCAGACGTTGGTCAACTCCGTCAACTCCAGCATCCCCAAGGCCTGCTGCGT 1112 
Query 294 GCCCACGGAGCTGAGCGCCATCTCCATGCTCTACCTGGATGAGTATGACAAGGTGGTGCT 353 
I I I I I I I I M M M I I I I I I M M I I I I I I I I I M I I i l M I I M I I I I i l l l l l l l l l l 
Sbjct 1113 GCCCACGGAGCTGAGCGCCATCTCCATGCTCTACCTGGATGAGTATGACAAGGTGGTGCT 1172 
Query 354 GAAAAACTACCAGGAGATGGTGGTGGAGGGGTGCGGGTGCCGCTGAC 400 
M M I I I M I I I M M I I M I I I M M I I I M I I I I I I I I M I I I I I 
Sbjct 1173 GAAAAACTACCAGGAGATGGTGGTGGAGGGGTGCGGGTGCCGCTGAC 1219 
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Appendix 5. Verification of mcBMP4 insert identify and orientation in PGEX-KG 
E. coli. expression vector by DNA sequencing. 
HteOTO 
'$r 
<H»A:ST3IC:tt 
^ — 
: lMlHOMtSmcOVUK 
IS U H 45 " 15 ~ g " ?! TJ 1 ! J55 u5 i S £35 
nCCfr99C9TTCTWTOQCRCMWACT9CQGC7YOCC1STQ0CGflftCGICC1ICnW3OCMCMCCM9GC&VC^OCMM9rcMVCMC^ 
IKXOOOOMAftASnOOB^XMVl «ee*wo«e^K!«i*«aMOTi*CT»»e»i«fw»wi«w»icwe^ 
ICMTCSWA WfWMCCflCIC T<BWSMTJCOCWMMJHCfiCH WIG* * WAJUWWMW(WBflBWW(M0»CfclOTflBWOCOCCTWCCnWfW<WWTf#Ctt<WTTt1SI00d6CAAICW* 
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Appendix 6. Chick BMP4 DNA sequence (Open Reading Frame) and translated chick 
BMP4 protein sequence. cBMP4 DNA sequence is showed in black while cBMP4 
protein sequence is showed in blue. Mature region of cBMP4 protein is highlighted in 
yellow. The potential glycosylation sites are marked in boxed letters. 
M I P G N R M L M V I L L C Q V L L G G 
1 atgattcctggtaaccgaatgctgatggtcatcctactatgccaagtcctgctgggaggt 60 
T N H A S L I P E T G R K K V A E L Q G 
61 accaaccatgctagcctgatccccgagaccggcaggaagaaagtcgcagagct[t]caggga 12 0 
Q A G S G R R S A Q S H E L L R G F E T 
121 caagccggatccggacgccgctctgcccaaagccatgaactcttgcggggtttcgaaacg 180 
T L L Q M F G L R R R P Q P S K S A V I 
181 actctgctgcagatgtttgggctgcga§ggcggccccagcccagcaaatcagccgtcatc 240 
P S Y M L D L Y R L Q S G E E E E R S L 
241 cccagttacatgctggatctctaccggctccagtccggagaagaggaggagaggagcctc 3 00 
Q E I S L Q Y P E R S A S R A N T V R S 
3 01 caggagatcagcctgcagtacccggagcgatctgccagccgg|g]ccaacaccgtgaggagc 3 GO 
F H H E E H L E S V P G P S E A P R I R 
3 61 t|t]ccaccatgaagagcacctggagagcgtgccgggtcccagcgaagcgccgcggatccgc 420 
F V F N L S S V P D N E V I S S E E L R 
421 ttcgtcttcaacctcagcagcgtgccggacaacgaggtgatctcgtcggaggagctgcgg 4 80 
L Y R E Q V E E P S A A W E R G F H R I 
481 ctgtaccgggagcaggtggaggagccgagcgcggcgtgggagaggggcttccaccggata 540 
N I Y E V M K P L S E R S Q A I T R L L 
541 aacatttacgaagtgatgaagccgctgtcggagcgctcgcaggccattacgcgcctgttg 600 
D T R L V H H N V T R W E T F D V S P A 
601 gacacgcggttggtgcaccacaacgtgacgcgctgggagacctttgatgtgagcccagcc 660 
V I R W T K D K Q P N H G L V I E V T H 
661 gtgatccggtggaccaaggacaagcagcccaaccacgggctggtgatcgaggtgacccac 720 
L H Q A Q T H Q G K H V R I S R S L P Q 
721 ctccaccaggcacagactcatcagggcaaacacgtcaggattagccgatctttacctcag 780 
G H G G D W A Q L R P L L V T F G H D G 
781 gggcacggcggggactgggcgcagctcaggccgctcctggtcaccttcgggcacgacggg 84 0 
R G H A L T R R A R R S P K H H G S R K 
841 cgaggccacgcgctgacccgcagggcccgccgcagccccaagcaccacggttcccgcaag 900 
N K K N C R R H A L Y V D F S D V G W N 
901 aacaaaaaaaactgccgccgccacgctctctatgtggatttcagcgacgtgggttggaac 960 
D W I V A P P G Y Q A F Y C H G D C P F 
961 gattggatcgtggcccccccgggctaccaggcgttttactgccacggggactgccccttc 1020 
P L A D H L N S T N H A I V Q T L V N S 
1021 cctctggccgaccacctcaactccaccaaccacgccatcgtgcagacgttggtcaactcc 10 80 
V N S S I P K A C C V P T E L S A I S M 
1081 gtcaactccagcatccccaaggcctgctgcgtgcccacggagctgagcgccatctccatg 114 0 
L Y L ' D E Y D K V V L K N Y Q E M V V E 
1141 ctctacctggatgagtatgacaaggtggtgctgaaaaactaccaggagatggtggtggag 1200 
G C G C R * 
1201 gggtgcgggtgccgctga 
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Appendix 7. List of commonly used abbreviations in this study. 
Abbreviation 
AVCD 
ASP 
OT 
AVC 
EMT 
TGF-/3 
BMP 
PBSM 
IPTG 
YTA 
GST 
CDNB 
GST 
KLH 
GLUT 
PMSF 
Full Term 
atrioventricular canal defect 
atrial septum primum 
outflow tract 
atrioventricular canal 
epithelial-mesenchymal transformation 
transforming growth factor- (8 
bone morphogenetic proteins 
parabronchial smooth muscle 
isopropyl-/3-D -thiogalactoside 
Trytone yeast ampicillin 
1 -chloro-2,4-dinitrobenzene 
1 -chloro-2,4-dinitrobenzene 
glutathione S-transferase 
keyhole limpet hemocyanin 
glutaraldehyde 
phenylmethanesulphonylfluoride or 
phenylmethylsulphonyl fluoride) 
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